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ABSTRACT 
 
T-cell Dysfunction by HCV Core Protein Involves PD-1/PD-L1 Signaling 
 
by 
Ellis King 
 
In 1989 the hepatitis C virus was identified as a significant cause of post-
transfusion hepatitis.  Nearly two decades later there is still no vaccine, 
inadequate treatment options, and limited understanding of how the virus 
establishes chronicity in the majority of the people it infects.  Recent reports 
suggest that the interaction of a negative co-stimulatory pathway mediated by 
PD-1 and PDL-1 is associated with persistent viral infection.  The role, if any, that 
PD-1/PDL-1 has in HCV infection is unknown.  In this study we report that PD-1 
is upregulated in T-cells from persons with chronic HCV infection when 
compared to healthy donors.  In addition, PD-1 and PDL-1 are upregulated on T-
cells from healthy donors when exposed to extracellular HCV core protein (a 
nucleocapsid protein that is immunosuppressive); upregulation of PD-1 is 
mediated by core’s ability to bind to the complement receptor gC1q.  We also 
report that the observed T-cell function can be restored by blocking the PD-
1/PDL-1 interaction.  Our results indicate that HCV core can upregulate an 
important negative T-cell signaling pathway that is associated with viral 
persistence.  This upregulation of PD-1/PDL-1 represents a novel and perhaps 
 2
shared mechanism that viral pathogens may use to subvert the human immune 
response.  It also represents a potential new treatment option for the millions of 
people who suffer from chronic hepatitis C infection. 
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CHAPTER 1 
 
INTRODUCTION 
 
A Brief History of Post-Transfusion Hepatitis 
 
The possibility and need for large scale transfusion medicine came 
together in the 1940s.  Medical science had advanced sufficiently to provide the 
possibility and World War II provided the need.  So, began the establishment and 
growth of blood banks, transfusion services, and other related laboratory support.  
It was quickly realized that hepatitis could be transmitted via blood or blood 
products when post-transfusion hepatitis (PTH) was first reported in the U.S. by 
(Beeson 1943).  However, the demand for blood continued to grow and by the 
early 1970s there were over 5000 organizations involved in transfusion medicine 
with over 12 million units of whole blood transfused per year (Domen 1995).  The 
increased demand brought increased disease transmission; an NIH study during 
this time reported that the risk of PTH was 6.3% when a patient was transfused 
with blood from a commercial donor and <0.6% for blood from a  volunteer donor 
(Walsh and others 1970). 
In 1965 the first marker for PTH was identified and termed the Australian 
antigen (Blumberg and others 1965).  By 1970 the Australian antigen had been 
re-named as the hepatitis B surface antigen (HbsAg) (Gocke and others 1969; 
Gocke and others 1970) and in 1972 the FDA required all blood donations within 
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the  U.S. to be screened for HBsAg (Hoofnagle 1990).  These efforts and the 
FDA decision to disallow commercial donors (persons who donate blood for 
money) lowered the PTH rate to 7.1% of the prior rate (Alter and others 1972).  
The next major discovery was in 1973 (Feinstone and others 1973) when the 
hepatitis A virus (HAV) was identified as an agent of acute hepatitis.  However 
within a few years, it was determined that HAV was not the cause of the non-
HBV cases of PTH (Dienstag and others 1977; Stevens and others 1978).  The 
still unidentified agent of hepatitis was termed non-A, non-B hepatitis (NANBH) 
and represented 90% of residual PTH cases in the 1970s and early 1980s.   
It was not until 1988 that a new hepatitis virus was identified by Houghton 
and associates at Chiron in collaboration with Bradley of the Hepatitis Branch of 
the Centers for Disease Control (Ezzell 1988).  Choo and others then used a 
cDNA library generated from a patient with NANB hepatitis to screen the serum 
of a patient with chronic NANBH.  A complementary DNA clone was isolated that 
was shown to encode an antigen associated specifically with NANBH infections 
(Choo and others 1989).  This positive clone and this new virus were associated 
and named hepatitis C virus (HCV).  
 
Hepatitis C Virus 
Since 1998 the Centers for Disease Control and Prevention (CDC) 
estimate that >40,000 new infections with hepatitis C virus (HCV) occur every 
year making HCV infection the most common chronic bloodborne viral infection 
in the United States.  The third National Health and Nutrition Examination Survey 
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(NHANES III) based on data collected from 1988-94, found that within the 
civilian, non-institutionalized U.S. population 3.9 million American were infected 
with 2.7 million chronically infected.  If this prevalence rate of 1.8% is 
extrapolated to today’s population of 300 million then >5 million Americans are 
presently infected with nearly 3.5 million chronically infected.  These estimates 
are likely conservative due to the exclusion of incarcerated (infection rates 
estimated to be 15-40%, CDC) and homeless persons, groups that generally 
have a high prevalence of HCV infection.  Presently, most HCV infected persons 
are adults between the ages of 30-49 years old (Alter and others 1997; Alter 
1997).  Given that HCV infection can take years to become clinically significant, 
most persons are probably infected in their early adulthood.  Males are almost 
twice as like to be infected compared to females. 
As shown in Figure 1.1, the greatest present day risk of HCV infection 
comes with injecting drug use.  Of persons injecting drugs for at least 5 years, 
60% to 80% are infected with HCV compared to an approximately 30% infected 
with HIV. 
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 Figure 1.1  Sources of Infection for Persons with Hepatitis C.  * Hemodialysis; health-care work; 
perinatal.  Source – CDC 
 
Current screening and testing procedures for donated blood have reduced the 
likelihood of contracting HCV from a transfusion to less than one per million units 
transfused.  These same procedures, plus virus inactivation procedures, have 
allowed only one instance of infection from contaminated blood products since 
the testing/screening procedures were put in place in the U.S.  Although the risk 
from sexual intercourse is low, sex is a common behavior in the general 
population.  So, while other types of exposure have a relatively greater risk (e.g., 
transfusion from an infected donor), they account for a relatively small proportion 
of the population in whom these exposures have occurred.  The remaining 
groups at risk – health care worker exposure, vertical transmission from mother 
to child, and persons undergoing hemodialysis account for approximately 5% of 
new infections.  Approximately 10% of infected persons have no recognized 
source for their infection. 
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Preventing and treating HCV is problematic.  Currently no vaccine exists 
and no likely candidates are in the near future.  In the U.S., HCV genotypes 1a 
and 1b are most prevalent (Hoofnagle 1997) and the most resistant to the 
currently recommended therapy of pegylated interferon alpha and ribavirin 
(Hoofnagle 2003).  Peginterferon alpha and ribavirin will achieve a sustained 
elimination of HCV infection for at least 6 months in 30% to 40% of patients who 
complete their therapy.  An additional 10% to 20% of patients do not complete 
the therapy due to the side effects of the medication or have contraindications 
(such as sever cirrhosis) that prohibit treatment.  This combination treatment will 
also induce a sustained virologic response (SVR) in 42-48% of persons infected 
with genotype 1a or 1b, whereas the same treatment will induce a SVR in 76-
88% of persons infected with genotypes 2 or 3 (Fried and others 2002).  
Additional contra indicators also exist.  IFN alpha is associated with depression 
and ribavirin can cause neutropenia and can have a teratogenic effect.  Current 
antiviral therapy is not approved for patients below the age of 18. 
The study of HCV is made difficult by two key factors.  HCV will only 
reliably infect humans and chimpanzees, thus limiting animal models.  
Additionally, in vitro replication is very poor (although some replicon systems 
have been made to work in hepatocytes.)  Because newly infected persons are 
usually asymptomatic and, therefore, almost never clinically recognized as 
infected, it has also been difficult to determine the initial immune responses that 
correlate with viral clearance.  To further compound the issue, it appears that the 
six major genotypes described (Simmonds and others 1993a) may have different 
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disease patterns and different responses to treatment (Hoofnagle and di 
Bisceglie 1997).  Finally, in spite of strong evidence linking HCV infection to 
numerous conditions involving the immune system, diseases associated with 
immune dysfunction occur frequently in persons without HCV infection, and so it 
has been difficult to confirm strong associations between HCV and a given 
disease. 
Hepatitis C is a 9.5-kb positive strand RNA virus of the Flaviviridae family.  
The genome consists of ~9500 nucleotides encoding a single polypeptide of 
~3000 amino acids that is cleaved into structural and non-structural proteins.  It 
encodes three structural proteins (core, E1, and E2) and at least six non-
structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B).  HCV is 
classified into 6 distinct but related genotypes; HCV is further divided into over 50 
subtypes based on sequence variation in the core and E1 genes and also shows 
significant geographical variation (Simmonds and others 1993b).  Persons with 
long-term infections also tend to have greater levels of genetic diversity within 
their genotypes (quasispecies) (Honda and others 1994; Farci and others 1997), 
most likely due to the poor fidelity of the HCV RNA polymerase.  The phenomena 
of high levels of quasispecies is also associated with poor clinical prognosis 
(Kanazawa and others 1994), that may be linked to the poor CTL response in 
chronically infected persons. 
A remarkable feature of HCV is its ability to evade the host immune 
response, resulting in chronic infection for over 80% of persons exposed.  The 
high incidence of persistent infection with HCV suggests that this virus has 
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evolved one or more mechanisms to evade and possibly suppress the host 
immune response.  Chronic HCV infections are associated with liver cirrhosis 
and hepatocellular carcinoma and have become a leading indicator for liver 
transplant in the U.S. (Hoofnagle 1997).   Cirrhosis of the liver develops in 10% 
to 20% of persons with chronic hepatitis C over a period of 2-30 years, and 
hepatocellular carcinoma (liver cancer) in 1% to 5% of those with cirrhosis.  In 
addition to cirrhosis and carcinoma, persons infected with HCV are also at a 
significant risk of developing autoimmune diseases such as glomerulonephritis 
and mixed cryoglubulinemia (Agnello and De Rosa 2004).  Hepatitis C disease 
progression varies greatly from person to person making it not only difficult to 
predict who will develop chronic disease but also which of the chronically infected 
will go on to develop significant sequellae.  One thing that is known is the impact 
of alcohol use in infected persons.  Chronically infected persons who abuse 
alcohol have a greater risk of developing cirrhosis and also be refractory to the 
effect of any anti-viral medication.   
While the precise mechanisms for how the disruption of the host immune 
response by HCV can result in various immune disorders have yet to be defined; 
however it is apparent that HCV modulates host immunity on several different 
levels (Moorman and others 2001b).  Over the past decade, there have been 
numerous studies examining different facets of HCV-associated immune 
dysfunction that have included B-cell, T-cell, NK cell, and dendritic cell 
dysregulation (King and others 2007).  The significance of such 
immunomodulatory potential appears to be twofold: evasion of the host immune 
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response leading to viral chronicity, and the potential for development of 
lymphoproliferative disorders.  
It is noteworthy that HCV clearly infects multiple extrahepatic cell types, 
including peripheral blood mononuclear cells, and this is observed both in vivo 
and in vitro (Shimizu and others 1992; Shimizu and others 1997; Lerat and 
others 1998; Radkowski and others 2000; Radkowski and others 2002; Nowicki 
and others 2005).  It is therefore possible that the immune dysfunction observed 
in HCV is a function of its ability to infect such cells, although the frequency of 
this infection appears low (Bronowicki and others 1998).  HCV sequences 
observed in different cellular compartments and in particular peripheral blood 
mononuclear cells may vary, suggesting viral tropism for specific cells that may 
be in part affected by the HCV diversity that occurs as quasispecies develop 
(Lerat and others 1998).  The role of a given genotype in targeting hematopoetic 
cells remains controversial (Kao and others 1997; Lerat and others 1998). 
 
Dysregulation of B Cell Function Mediated by HCV
Because the association between chronic HCV infection and both mixed 
cryoglobulinemia and B-cell lymphoma was first recognized, there have been an 
increasing number of studies examining B cell dysfunction in the context of 
chronic HCV infection.  While it has clearly been shown that clonal populations of 
B lymphocytes are disproportionately present in increased numbers in patients 
with chronic HCV infection, there are also numerous data detailing specific 
mechanisms behind B cell clonality.  Moreover, such mechanisms offer insight 
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into the presence of immune dysfunction in patients with chronic HCV infection.  
Most notably, B cells have become a target of drug development for the 
treatment of certain HCV-associated immune diseases (Kazkaz and Isenberg 
2004). 
(Franzin and others 1995), were the first to report the presence of clonal B 
cell expansion in the peripheral blood of 38 HCV-infected patients. Subset 
analyses in their study revealed the presence of clonal immunoglobulin gene 
rearrangements in 100% of HCV-positive patients with type II mixed 
cryoglobulinemia (MC) as opposed to only 24% in HCV-positive patients without 
mixed cryoglobulinemia. The reversibility of B cell clonality in chronic HCV 
infection was similarly assessed in a cohort of 20 patients with HCV-associated 
MC undergoing interferon alpha therapy (Mazzaro and others 1996).  While 80% 
of these patients (all of whom were noted to have clonal populations of B cells) 
achieved complete or partial clinical responses, 15% reverted to polyclonal B cell 
populations following therapy. Recent studies also suggest upregulation of B-
lymphocyte stimulator (BLyS) in the setting of MC (Fabris and others 2006; Sene 
and others 2006), further supporting a significant relationship between clonal 
expansion of B lymphocytes and HCV-associated mixed cryoglobulinemia.  
(Zignego and others 2000), found an increased frequency of bcl-2 gene 
rearrangement (Mazzaro and others 1996; Nowicki and others 2005) in a 
prospective study of individuals with HCV and mixed cryoglobulinemia (Antonelli 
and others 2002), while (Toubi and others 2004), observed enhanced B cell 
apoptosis in B cells from chronically infected HCV patients.  There was relative 
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resistance to apoptosis seen in the CD95/Fas+ B cell subpopulation, suggesting 
a potential role for this subpopulation in B cell proliferative disorders. 
As the propensity of HCV to induce lymphoproliferation in patients with 
HCV-associated mixed cryoglobulinemia has been further elucidated, there has 
been some effort to define the underlying mechanisms.  (Machida and others 
2005), reported that an HCV E2-CD81 interaction modulates host B cell 
responses by enhancing activation-induced cytidine deaminase (AID) and 
hypermutating V(H) immunoglobulin genes in B cells, suggesting a mechanism 
for HCV-associated B cell lymphoproliferative disorders.  HCV E2 was also 
shown to activate the JNK pathway leading to preferential proliferation of CD27+ 
B cells (Rosa and others 2005).   
The effect of HCV core protein on molecular profiling in human B-
lymphocytes was recently examined by (Wu and others 2006), who found 
dramatic evidence for inhibition of B lymphocyte apoptosis by HCV core in 
several steps of the apoptotic cascade. The investigators expressed HCV core in 
an adenoviral vector in a healthy population of human B lymphocytes and 
observed down regulation of MHC class II molecules and caspase-1 and -4, 
which are proapoptotic proteins.  Up regulation of nuclear factor kappa light 
peptide inhibitor gene and TATA box protein, both of which are associated with B 
cell lymphoma, was also observed.  These findings underscore the potential of 
HCV to disrupt antigen presentation and apoptosis and may indicate yet another 
mechanism for HCV-related autoimmunity and lymphoproliferation. 
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Oncogenes have also been a focus of investigation in patients with MC.  
In a prospective study of 37 patients with HCV-associated mixed 
cryoglobulinemia, (Zignego and others 2000), found that 75.7% had bcl-2 
rearrangements in peripheral blood mononuclear cells, as opposed to 37.6% of 
patients with chronic HCV infection without mixed cryoglobulinemia (Antonelli 
and others 2002). (Galli-Stampino and others 2003), further expanded on the 
relationship between oncogenesis and clonal B cell expansion in patients with 
HCV-associated mixed cryoglobulinemia by demonstrating the presence of 
restricted V(H)I gene sequences in peripheral blood, hepatic, and lymph node B 
lymphocytes in three of four patients (Galli-Stampino and others 2003).  These 
gene sequences are usually associated with B-cell non-Hodgkin’s lymphoma 
(NHL) and their presence in patients with chronic HCV patients may indicate a 
mechanism of developing NHL through non-malignant, clonally expanded B-cell 
populations. 
 
Type I Interferon Dysregulation
Interferon-alpha stimulation is a critical and non-specific response to viral 
infection.  Its two main effects are induction of an anti-viral state in infected cells 
and interferon receptor ligation that results in activation of Janus kinase (Jak) and 
signal transducer and activator of transcription (STAT).  Jak/STAT signaling in 
turn activates numerous interferon-response genes including 2’-5’ oligoadenylate 
synthetase (OAS), Mx proteins and the double-stranded RNA dependent protein 
kinase (PKR) (Katze 2002).  PKR is induced by double stranded viral RNA and, 
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in-turn, phosphorylates eukaryotic initiation factor 2 (elF-2), resulting in inhibition 
of cellular protein syntheses and viral replication.  Two HCV proteins, the 
envelope glycoprotein E2 and the nonstructural protein NS5A, have been 
reported as potential inhibitors of the IFN response (Taylor 2000; Pflugheber and 
others 2002).  
Phosphorylated interferon regulatory factor 3 (pIRF-3) is the key 
transcription regulatory factor for type I interferon (Foy and others 2003).  Type I 
interferon, in turn, upregulates expression of double-stranded RNA-dependent 
protein kinase (PKR) that is a negative regulator of cell growth.  Recently, the 
HCV protein NS3/4A (a serine protease) was shown to interrupt the IFN signaling 
pathway.  Thus, in the presence of NS3/4A, IRF-3 is never phosphorylated and 
IFN production is not induced (Foy and others 2003).  The importance of IRF-3 
was also demonstrated with mutations resulting in dominant negative or 
constitutively active IRF-3 leading to enhanced or restrained HCV replication, 
respectively. 
 
Dysregulation of the NK Response 
Natural killer (NK) cells play a critical role in innate immunity.  NK cells 
mediate lysis of target cells by releasing cytotoxic granules that contain perforin 
and granzymes or by binding apoptosis inducing receptors on the target cells.  
NK cells also secrete numerous cytokines including IFN-gamma and TNF-alpha 
during inflammation (Poccia and others 2001).  Recent reports have implicated 
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the HCV E2 protein in suppression of NK activity (Crotta and others 2002; Tseng 
and Klimpel 2002). 
The HCV E2 protein binds CD81, which is expressed on the surface of 
host cells.  When NK cells are exposed to immobilized E2 or anti-CD81 (in vitro), 
their function is impaired.  The impairment ranges from suppression of 
cytotoxicity and IL-2 induced proliferation to suppression of IL-2, IL-12, and IL-15 
mediated induction of IFN-gamma (Crotta and others 2002; Tseng and Klimpel 
2002).  Additionally, ligation of CD81 by E2 inhibits CD16-mediated activation of 
extracellular signal-regulated kinase (ERK) and mitogen-activated protein kinase 
(MAPK) in NK cells (Crotta and others 2002).  These mechanisms, if employed 
by HCV, could facilitate HCV persistence.  However, this possibility needs further 
research as NK cells do not play a role in all viral infections. 
 
Dysregulation of Dendritic Cells by HCV Envelope Glycoproteins 
One possible cause of an impaired CD8+ response to HCV infection may 
be abnormal dendritic cell (DC) function preventing appropriate antigen 
processing and presentation.  Interestingly, HCV E1 and E2 glycoproteins 
interact with DC-specific intercellular adhesion molecule 3 (ICAM-3), 
sequestering nonintegrin (DC-SIGN) and its receptor, DC-SIGNR, in immature 
DCs (Lozach and others 2003; Pohlmann and others 2003).  The role of HCV 
interactions with DC remains controversial.  Numerous studies demonstrate 
abnormal DC activity in chronic HCV patients, yet recent studies by (Longman 
and others 2005), report the converse. 
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In addition to envelope proteins, HCV core has also been implicated in 
inhibiting DC and macrophage function (Sarobe and others 2003).  Addition of 
extracellular core or expression of core/E1 in mice by recombinant adenovirus 
demonstrated an effect on DC maturation and T cell responses upon allogenic 
stimulation.  A molecular mechanism(s) has not fully elucidated to explain this 
inhibition. 
 
Dysregulation of T Cell Function Mediated by HCV Core Protein
Evidence suggests that the 21kD HCV core protein, the first to be 
synthesized during infection, contains multiple functions that have numerous 
downstream effects on immune related cellular responses.  This 
immunomodulatory effect has been demonstrated by the suppression of anti-viral 
CTL activity (Large and others 1999b) and diminished T cell responses to HBV 
envelope proteins in mice immunized with HCV-core/HBV chimeric constructs 
(Geissler and others 1998).  HCV core has also been found circulating in the 
bloodstream of infected patients (Maillard and others 2001) suggesting that the 
effects of core may extend beyond the specific cells that are infected with HCV.  
This is important because in relative numbers, HCV infects few peripheral blood 
mononuclear cells (PBMCs) (e.g. lymphocytes).  Furthermore, extracellular HCV 
core has been shown to inhibit the T lymphocyte responses that are crucial for 
viral clearance (Kittlesen and others 2000; Yao and others 2001a), thus implying 
a role for core in establishing chronicity.  It is well known that, in general, an early 
and sustained virus-specific T-cell response is critical for viral clearance (Missale 
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and others 1996; Cooper and others 1999; Gerlach and others 1999; Gruner and 
others 2000; Takaki and others 2000; Thimme and others 2001).  However, in 
patients who are chronically infected with HCV, the frequency of virus specific T-
cells is relatively low.  Furthermore, the effector functions of HCV specific 
CD4+/CD8+ cells as well as the production of Th1-type cytokines (e.g. IL-2 and 
interferon gamma) are severely decreased (Rehermann and others 1996; Chang 
and others 1997; Lechmann and others 1999; Wedemeyer and others 2002; 
Sugimoto and others 2003).  It is clear that HCV will establish a chronic infection 
in most persons who are infected.  The available data strongly support the 
thought that HCV, through some action(s), suppresses the human immune 
system, thus establishing chronicity.  The available data also strongly suggest 
that the HCV core protein has a significant, yet not fully understood role, in the 
immune suppression. 
Studies have implicated that gC1qR (the glycoprotein portion of the C1q 
cellular receptor) is the cellular target of core protein (Kittlesen and others 2000).  
The natural ligand for gC1qR is C1q.  C1q is an integral part of the C1q complex 
that is well established as the first component in the classical pathway of 
complement activation, thus playing a critical role in the early defense against 
foreign antigens (Ghebrehiwet and others 2001).  The 33kD gC1qR and the 
60kD cCqR bind the globular “head” and collagen-like “stalk” domains of C1q, 
respectively, and form a hetrodimer that is expressed in most cell types, including 
T cells (Ghebrehiwet and others 2001).  Interestingly, treatment of PBMCs with 
extracellular HCV core leads to suppression of T-cell proliferation in a manner 
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similar to that observed when T-cells are exposed to C1q (Chen and others 
1994; Kittlesen and others 2000).  This suppressive effect can be abrogated by 
the addition of anti-gC1qR suggesting that core is indeed mediating suppression 
through gC1qR.  Therefore, the interaction between HCV core and gC1qR may 
provide the virus with a means to affect the human host immune response. 
gC1qR has also been reported to interact with several other viral and 
bacterial proteins potentially providing other micro-organisms with a “shared” 
mechanism of immune evasion (Luo and others 1994; Bruni and Roizman 1996; 
Wang and others 1997; Matthews and Russell 1998; Braun and others 2000; 
Nguyen and others 2000).  These data suggest that numerous human pathogens 
exploit a similar strategy to subvert the host immune response.  The underlying 
mechanisms for the role of gC1qR in the interference of the immune system have 
yet to be elucidated with regards to HCV infection as well as the other pathogens 
that may use this pathway.  It is, however, clear that the ability of HCV core to 
alter the immune response is not as simple as it binding to gC1qR.  In vitro 
studies show that HCV core from genotype 1a will dampen the host immune 
response (Yao and others 2006b), while other in vivo studies using HCV core 
from genotype 1b conducted in transgenic mice report no such effect (Liu and 
others 2002).  This suggests that the immunosuppressive effects may be 
genotype specific, and, indeed, this has been reported (Sugimoto and others 
2005).  Another in vitro study conducted in HepG2 cells reported that HCV core 
genotype 1a will significantly suppress nuclear factor kappa-B (NF-kB) when 
compared to genotype 1b (Ray and others 2002).  NF-kB is a well-known 
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transcription factor that is important in many cellular immune responses, as many 
of its target genes; such as interferon beta, TNF alpha, IL-2, IL-6, and IL-8 are 
immunologically relevant (Pellegrini and Schindler 1993).  Yet, patients who are 
infected with HCV genotype 1b still become chronically infected, further 
suggesting host factor(s) impact whether a newly infected person clears the virus 
or becomes chronically infected.  This is supported by studies conducted in 
chimpanzees that showed the level of innate expression of gC1qR will affect 
core’s ability to suppress the immune system.  Chimpanzees that had lower 
levels of gC1qR expression were more likely to resolve the HCV virus challenge 
versus those chimpanzees with higher levels of innate gC1qR expression (Yao 
and others 2006a). 
To date and with regard to HCV core-gC1qR binding and any subsequent 
immune suppression, most of the data produced have come from work in 
lymphocytes; lymphocytes obtained from either cell lines, such as Jurkats, or 
primary lymphocytes isolated from human volunteers.  One notable exception 
was a set of experiments conducted in normal human lung fibroblasts (NHLF) 
cell line.  The impetus for this study was reported links of HCV infection to 
declines in pulmonary function in patients with underlying pulmonary diseases 
such as asthma and chronic obstructive pulmonary disease (Kanazawa and 
others 2003; Kanazawa and Yoshikawa 2004).  The study investigators focused 
on IL-8 stimulation given its known role in mediating inflammatory pulmonary 
processes and general pulmonary pathology (Kaplanski and others 1997; Polyak 
and others 2001; Mukaida 2003).  They found that when HCV core is added to 
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cultures of NHLFs in an extracellular manner, IL-8 mRNA and protein are 
stimulated in a dose and time dependent manner (Moorman and others 2005b).  
They also reported that this up-regulation could be blocked by the addition of 
anti-gC1qR that blocks the core binding site on gC1qR.  While more studies need 
to be conducted in this area, this study offers an intriguing glimpse toward other 
(non-PBMC) possible ramifications of interactions between core and gC1qR. 
The early lymphocyte work investigating the consequences of core-gC1qR 
binding employed transfection methods in order to introduce core to the cell and 
focused on core’s ability to induce or up-regulate apoptosis of T-cells.  These 
studies found that transient expression of core appeared to up-regulate apoptosis 
mediated by interaction with members of the tumor necrosis family of receptors 
(TNFR) (Hahn and others 2000; Zhu and others 2001; Moorman and others 
2003).  It was found that expression of core sensitized Jurkat cells to FasL 
induced apoptosis (Hahn and others 2000) mediated by the cytoplasmic domain 
of Fas.  Additional studies also indicate that core can induce ligand independent 
apoptosis of Jurkats by activating caspase 3 and 8.  This same study also 
reported that intracellular expression of core can also induce Fas multimerization 
at  the cellular level as a  means of activating the apoptotic pathway (Moorman 
and others 2003).  While the evidence indicating that expression of HCV core will 
induce apoptosis in a T-cell cell line is strong, it is worth remembering that, as 
noted earlier, HCV infects a relatively low number of PBMCs.  Yet, in spite of 
HCV trophism for lymphocytes, the immune system can still produce HCV 
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specific T cells and HCV antibody, neither of which have significant efficacy given 
the high rate of chronicity. 
While inducement of apoptosis in T-cells may have a role in HCV 
establishing a chronic infection, it is likely that T-cell inhibition or suppression 
plays a larger role.  The search for a molecular basis for HCV core’s ability to 
suppress the immune system has identified several possibilities, all mediated by 
core’s ability to bind to gC1qR.  Core was first found to inhibit proliferation in 
activated T-cells by blocking the phosphorylation of extracellular signal-regulated 
kinase (ERK) and mitogen-activated ERK kinase (MEK) (Yao and others 2001a) 
in activated T-cells. HCV core-induced impairment of ERK/MEK mitogen-
activated protein kinase resulted in the inhibition of IL-2 and IL-2R gene 
transcription that led to the inhibition of IL-2 production and high-affinity IL-2R 
alpha expression. Importantly, the ability of anti-gC1qR Ab treatment to reverse 
HCV core-induced inhibition of ERK/MEK phosphorylation reveals that the 
interaction between HCV core and gC1qR is linked to the interference of 
ERK/MEK mitogen-activated protein kinase activation.  HCV core has also been 
shown to inhibit cell cycle progression from G1 to S phase by stabilizing p27Kip1, 
which is a negative regulator of Cdk4/cyclin D and Cdk2/cyclin E (Yao and others 
2003) complexes.  These cyclin dependent kinases (Cdk) and their cyclin 
partners serve to phosphorylate proteins that push cells from G1 to S phase.  
Therefore, stabilization of proteins that inhibit these Cdk-cyclin complexes will in 
turn lead to inhibition of cell cycle progression. 
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Further studies have reported additional instances of core interfering with 
cellular signaling.  As previously mentioned, core will bind to the complement 
receptor gC1qR whose natural ligand is C1q and that C1q also delivers inhibitory 
signals to T-cells.  Recent studies have shown that the affinity of core for gC1qR 
is greater than that of C1q, and core appears to deliver stronger inhibitory signals 
than does C1q (Yao and others 2004).  These same studies also reported that 
CD8+ T-cells are more susceptible to core meditated inhibition than CD4+ cells 
most likely due to CD8+ cells having higher expression of gC1qR.  Based on 
previously reported data that indicated core had an inhibitory effect on ERK/MEK 
signaling in T-cells (Yao and others 2001a) the investigators searched for other 
inhibitory effects on signaling.  They focused on early signaling in the early 
stages of T-cell activation and found that core treated T-cells show a decrease in 
the expression of Src kinases, Lck, and ZAP-70 that may impede cell cycle 
progression (Yao and others 2004).  Some of the latest data regarding signaling 
inhibition was conducted using recombinant core from patients who had a 
chronic infection versus patients who had spontaneously resolved their infection.  
It was found that core from the chronic patients had a greater inhibitory effect 
possibly mediated by diminishing the phosphorylation of STAT1/3 that, in turn, up 
regulates the expression of SOCS1/3 (Yao and others 2006b), which are 
negative regulators of T-cell proliferation.  This finding is strengthened when 
siRNAs, designed against SOCS1/3, abrogated the core mediated T-cell 
inhibition. 
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Programmed Cell Death 1 (PD-1). 
In the early 1990s Honjo and colleagues began to search for gene 
products that contributed to apoptotic cell death that was dependent on de novo 
synthesis of RNA and protein e.g., the classical type programmed cell death.  
They began their work in four cells lines of consisting of T-cells, B-cells, and a 
lymphoid progenitor line.  In 1992 they reported that in two of the four cell lines 
de novo synthesis of RNA was necessary for apoptosis to occur.  Further work 
determined that a novel member of the immunoglobulin gene superfamily, 
termed program cell death 1 (PD-1), was linked to the observed apoptosis (Ishida 
and others 1992). 
By 2002 it had been reported that, in vivo, PD-1 was expressed 
predominately on activated T-cells (Iwai and others 2002).  Further studies 
indicated that cross-linking of PD-1 with its ligand would induce phosphorylation 
of its immunoreceptor tyrosine-based switch motif that would then recruit SHP-2 
with its subsequent negative regulatory signal (Okazaki and others 2001).  The 
ligands were then identified as PD-L1 (B7-H1) and PD-L2 (B7-DC) (Dong and 
others 1999; Freeman and others 2000; Latchman and others 2001; Tseng and 
others 2001) with PD-L1 shown to be expressed in numerous nonlymphoid tissue 
(Dong and others 1999; Freeman and others 2000).  The receptor-ligand 
distribution pattern, PD-1 expressed in activated T-cells and PD-L1 expressed in 
peripheral tissue, led to the hypothesis that PD-1/PD-L1 interaction might occur 
at the effector phase of the immune response when activated T-cells migrate to 
sites of inflammation or infection.  Beginning with known liver involvement in the 
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immune response, a set of experiments was designed around liver 
nonparenchymal cells (LNPCs).  It was found that PD-L1 was constitutively 
expressed on LNPCs and that this expression was essential to inhibit 
proliferation of activated T-cells in the liver (Iwai and others 2003), suggesting 
that the PD-1/PD-L1 interaction may play important roles in the negative 
regulation of immune responses in the liver. 
The pathways that memory CD8+ T-cells take after an acute viral infection, 
versus a chronic infection, are distinct (Wherry and others 2003; Wherry and 
others 2004; Klenerman and Hill 2005).  Memory CD8+ T-cells generated from an 
acute viral infection are, in general, highly functional and make up an important 
component of protective immunity.  On the other hand, memory CD8 T-cells 
generated from a chronic viral infection are often characterized by varying 
degrees of functional impairment that is the most likely reason the virus is able to 
establish a chronic infection.  However, even in viral infections that eventually 
become chronic, initial T effector cells are generated.  Yet, they soon lose 
function over the course of a chronic infection and become ‘exhausted’.  This 
exhaustion effect was first reported in mice with a chronic LCMV infection 
(Gallimore and others 1998; Zajac and others 1998) but was quickly shown to be 
a factor in humans with chronic viral infections; particularly those persons with 
human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C 
virus (HCV) (Letvin and Walker 2003; Pantaleo and Koup 2004; Rehermann and 
Nascimbeni 2005). 
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The next step taken was to determine gene expression in exhausted T-
cells versus functional T-cells in the mouse LCMV model.  PD-1 mRNA and 
protein was found to be significantly up-regulated in the exhausted T-cells 
(Barber and others 2006) when compared to the functional T-cells.  Further 
investigation by found that the LCMV strain that consistently causes an acute 
infection in mice had only transient up-regulation of PD-1 mRNA and protein, 
whereas the strain that consistently causes a chronic infection had higher and 
sustained levels of PD-1 mRNA and protein.  They then determined that by 
blocking the PD-1/PD-L1 interaction they could restore function, e.g. the 
exhausted T-cell where induced to clonally expand, to CD8+ cells even in the 
absence of CD4+ cells. 
 
Hypothesis 
Based on the available data the following hypothesis is considered: 
Persistence of HCV infection is mediated by the dysregulation of the PD-1 
pathway in T-cells via HCV core-gC1qR interaction. 
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CHAPTER 2 
 
T cell Dysfunction by HCV Core Protein Involves PD-1/PDL-1 Signaling 
 
Abstract 
 
Recent reports show that a negative T cell co-stimulatory pathway mediated by 
PD-1 and PDL-1 is associated with T cell exhaustion and persistent viral 
infection.  Persistent hepatitis C virus (HCV) infection in humans is also 
characterized by impaired T lymphocyte function, but the role of the PD-1 and 
PDL-1 pathway in HCV infection is unknown.  Here we report that T cells isolated 
from chronically infected HCV patients express significantly higher levels of PD-1 
when compared to healthy donors.  In addition, PD-1 and PDL-1 expression is 
up-regulated on T cells from healthy donors exposed to HCV core, a 
nucleocapsid protein that is immunosuppressive; up-regulation of PD-1 is 
mediated through interaction of HCV core with the complement receptor, gC1qR.  
Importantly, T cell functions that are dysregulated by HCV core, including T cell 
activation, proliferation, and apoptosis, can be restored by blocking PD-1 or PDL-
1 engagement.  Our results indicate that HCV core can up-regulate a key 
negative T cell signaling pathway associated with viral persistence and highly 
expressed on the T cells of persistently infected individuals.  This up-regulation of 
the PD-1 and PDL-1 pathway in humans represents a novel and perhaps 
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common mechanism by which a virus usurps host machinery to facilitate 
persistence. 
 
Introduction 
 
T cell dysfunction is a common feature of many persistent viral infections, 
although the underlining mechanism(s) remains poorly understood.  Hepatitis C 
virus (HCV) infection provides an excellent model to study the mechanisms of 
persistent viral infection as this virus is remarkable at evading host immune 
surveillance, resulting in chronic infection in the majority of infected individuals 
(Moorman and others 2001a).  Chronic HCV infection is associated with liver 
cirrhosis and hepatocellular carcinoma and has become a leading cause of liver 
transplantation in the United States (Lauer and Walker 2001).  Numerous studies 
have reported that effective T cell responses are crucial for viral clearance, and 
impaired viral specific CD4+ and CD8+ T cell functions are associated with 
chronic HCV infection (Gerlach and others 1999; Gruner and others 2000; 
Lechner and others 2000; Takaki and others 2000; Thimme and others 2001; 
Wedemeyer and others 2002; Shoukry and others 2003).   Other studies have 
suggested the possibility of a more non-specific immune dysregulation in the 
setting of HCV infection, perhaps supported by the high frequency of 
autoimmune disease in individuals with chronic HCV infection (Yao and others 
2001a; Yao and others 2001b; Lucas and others 2004; Graham and others 2005; 
Par and others 2006).  Despite extensive investigations into the mechanisms of 
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virus-mediated T cell dysfunction, it still remains unclear why a small percentage 
of HCV patients exhibit effective T cell responses and clear the virus following 
acute infection, while the vast majority fail to do so and progress to chronic 
infection. 
It is likely that a gene product(s) encoded by HCV directly affects T cell 
functions that are crucial for limiting virus replication, and thus facilitates 
persistent infection.  Several HCV-derived proteins, including the nucleocapsid 
core protein, may play a role in the impairment of host immunity either directly or 
through interaction with host molecules (Ray and Ray 2001; Eisen-Vandervelde 
and others 2004).  It has been previously demonstrated that HCV core protein is 
necessary and sufficient to suppress host immune responses in a murine model 
(Large and others 1999a).  The molecular mechanism of HCV core-mediated 
immunomodulation was subsequently determined by identifying a host-binding 
partner, C1q complement receptor-gC1qR, on human T lymphocytes (Kittlesen 
and others 2000).  C1q, the natural ligand for gC1qR, is the first molecule to be 
activated in the classical complement cascade and plays a critical role in 
modulating both innate and adaptive immunity (Ghebrehiwet and others 2001).   
Binding of C1q to gC1qR on T lymphocytes leads to suppression of T cell 
responsiveness (Chen and others 1994); similarly, HCV core can inhibit T cell 
responses through interaction with gC1qR (Yao and others 2001a; Yao and 
others 2003; Yao and others 2004).   Thus, the engagement of circulating HCV 
core protein with gC1qR displayed on the surface of T lymphocytes may provide 
the virus with a direct means of affecting host immunity (Yao and others 2001b). 
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In light of the observations that free core particles circulate in the 
bloodstream of HCV-infected patients (Masalova and others 1998; Maillard and 
others 2001), our findings may be particularly salient to the pathogenesis of HCV.  
It is notable that in addition to HCV core, gC1qR has been shown to interact with 
several viral and bacterial proteins, potentially providing these organisms with a 
“shared” mechanism of immune modulation (Ghebrehiwet and others 2001; Yao 
and others 2001b).  While the early events following the HCV core/gC1qR 
interaction have yet to be elucidated, T cell receptor (TCR) signaling pathways--
and in particular other negative regulatory pathways--would be prime targets for 
viral immunomodulation. 
The recently described PD-1 and PD-L inhibitory pathway represents just 
such a negative regulatory mechanism to maintain the intricate balance between 
positive and negative costimulatory signals delivered to T cells after antigenic 
encounter (Nishimura and Honjo 2001; Khoury and Sayegh 2004).  PD-1 
(programmed death-1) is an immunoinhibitory receptor predominantly expressed 
on activated T cells; its natural ligands include PDL-1 (also known as B7-H1, 
expressed on both haematopoetic and parenchymal cells) and PDL-2 (B7-DC, 
primarily expressed on monocytes).  Activation of the PD-1 pathway induces 
immunoreceptor tyrosine phosphorylation and recruitment of tyrosine 
phosphatases, including src-homology proteins (SHP-1/SHP-2), to deliver a 
negative signal to TCR activation pathways.  Evidence is emerging for the 
involvement of PD-1 inhibitory pathway in normal immune tolerance, autoimmune 
responses, and antitumor and antiviral immune evasion (Nishimura and Honjo 
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2001; Iwai and others 2003; Khoury and Sayegh 2004).  Perhaps most 
interesting, PD-1 was recently found to be selectively up-regulated on 
“exhausted” CD8+ T cells during chronic viral infection in mice (Barber and others 
2006).  In addition, very recent reports now show similar findings in the setting of 
HIV infection (Day and others 2006; Freeman and others 2006; Petrovas and 
others 2006; Trautmann and others 2006b). 
To further characterize underlying mechanism(s) of HCV-induced T cell 
dysfunction, we examined the role of PD-1 and PDL-1 expression on human T 
cells. We found that individuals with chronic HCV infection exhibit up-regulation 
of both PD-1 and PDL-1 on CD4+ and CD8+ T cell populations compared to 
healthy control populations.  To explore potential mechanisms for this up-
regulation, we exposed naïve healthy T cells to HCV core and found that 
expression of both PD-1 and PDL-1 are up-regulated, and this core-induced   
PD-1 and PDL-1 induction is gC1qR-dependent.  Importantly, blocking PD-1 and 
PDL-1 signaling pathway can restore HCV core/gC1qR-mediated T cell function, 
suggesting that the PD-1 pathway may be employed during HCV core/gC1qR 
interaction as a means of dysregulating T cell functions. 
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Materials and Methods 
 
 Subjects. 
 
 An IRB-approved protocol at ETSU has contributed to a database for the 
storage of blood samples from HCV-infected individuals.  Blood from healthy 
donors serves as a normal control.  Peripheral blood mononuclear cells (PBMC) 
were isolated from these subjects by Ficoll density centrifugation with lympholyte-
H (Cedarlane Labs, Ontario, Canada) and then cryopreserved in freezing 
medium (10% DMSO, 20% FBS in RPMI 1640) in liquid nitrogen until examined.  
Twelve chronically HCV-infected patients and seven healthy donors were 
selected, and their PBMC were thawed, washed, and counted for the following 
studies. One subject was co-infected with HIV but was a long-term 
nonprogressor with repeatedly negative HIV viral load.  All subjects had HCV 
infection detected by ELISA and confirmed by HCV RNA testing and none were 
considered to be acute infections. 
 
Reagents. 
 
Recombinant HCV core protein, NS3, and control β-galactosidase proteins 
were obtained from ViroGen (Watertown, MA).  These proteins have been used 
extensively in immunologic studies of HCV antigens and have been documented 
to be free of LPS or RNA.  Anti-CD3/CD28, anti-CD45RA/RO antibodies, and 
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FITC-conjugated anti-CD4 and CD8 antibodies were obtained from BD 
Pharmingen (San Diego, CA).  Anti-PD-1 and anti-PDL-1 were obtained from 
eBioScience. 
 
Flow Cytometry. 
 
To determine PD-1 or PDL-1 expression on the surface of T lymphocytes, 
1 x 106 PBMC from HCV patients or healthy donors were stimulated with or 
without anti-CD3/CD28 (1 μg/ml) in the presence of HCV core or a control 
protein, β-gal (2 μg/ml).  After 24 h treatment, the cells were washed in 
fluorescence-activated cell sorting (FACS) medium (RPMI 1640 supplemented 
with 10% FBS and 1% NaN3) at 200 x g for 5 min at 4 ºC.  The cells were 
counted and resuspended in 100 μl of FACS medium containing 20 μl PE-anti-
human PD-1 and PDL-1 conjugate (eBioScience) and 20 μl of FITC-anti-human 
CD4 and CD8 conjugate (BD Pharmingen) at 4 ºC for 1 h in the dark.  The cells 
were then washed three times and fixed with 1% paraformaldehyde in PBS 
before analysis by flow cytometry (Becton Dickinson, San Jose, CA).  The 
primary isotype controls were used to determine the level of background staining.  
20,000 events were collected after gating on lymphocyte populations and using 
consistent instrument settings to avoid bias. 
To determine the role of PD-1 and PDL-1 in HCV core-induced T cell 
inactivation,   PBMC were anti-CD3/CD28-stimulated and HCV core-treated as 
described above in the presence of anti-human PD-1 or PDL-1 or isotype control 
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antibodies (Santa Cruz) for 24 h, and CD69 cell surface expression was detected 
by incubating cells with PE-anti-human CD69 conjugate (BD Pharmingen) 
followed by FACS analysis (Yao and others 2003). 
 
RT-PCR. 
 
Purified PBMCs (2 x 106) were treated with or without HCV core protein (2 
μg/ml; ViroGen) for various time points (6, 12, 24, 48 h), and total RNA was 
isolated from these cells by the TRIzol method (Life Technologies).  A total of 1 
μg of RNA was treated with DNase to digest genomic DNA and 0.27 μg of RNA 
was then reverse transcribed using MuLV reverse transcriptase under conditions 
of 10 min at room temperature, 20 min at 42 ºC, 5 min at 99 ºC, and 5 min at      
4 ºC.  1 μl of 1:10 serially diluted cDNA generated in the RT reaction was added 
to the PCR reaction.  PCR was carried out using the following primer pairs: PD-1 
sense 5’-GCT CAG GGT GAC AGA GAG AAG-3’; antisense 5’-CAC CAA CCA 
CCA GGG TTT G-3’; β-actin sense 5’-CGA GCG GGA AAT CGT GCG TGA 
CAT-3’; antisense 5’-CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT-3’ for 
35 cycles of 95 ºC for 15 s, 58 ºC for 15 s, 72 ºC for 15 s, followed by a single 10 
min extension at 72 ºC.  To control for genomic DNA contamination, equal 
amount of cDNA from each sample were PCR amplified without RT.  The 
resulting PCR products were separated on a 2% BioGel (Bio 101, Carsbad, CA) 
and viewed by a multimager.  To examine whether gC1qR mediates the HCV 
core-induced induction of PD-1, a 1:10-diluted anti-gC1qR antibody or pre-
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bleeding control serum (kindly provided by Dr. Hahn) was coincubated with cells 
treated with core protein, and PD-1 mRNA expression was assessed as 
described above. 
 
T Cell Proliferation. 
 
The ability of anti-PD-1 or anti-PDL-1 to reverse the HCV core-induced T 
cell inhibition was evaluated by using Quick Cell Proliferation Assay (BioVision, 
Mountain View, CA).  Briefly, 1 x 105 of PBMC were stimulated with or without 
anti-CD3/CD28 in the presence of HCV core or β-gal protein.  Anti-PD-1 or anti-
PDL-1 or isotype control antibody (2 μg/ml, Santa Cruz) was added 
simultaneously and the cells were cultured for 24 h.  T cell proliferation was 
performed according to manufacturers’ instructions.  The absorbance of the 
treated and untreated samples was measured using a microtiter plate reader at 
420-480 nm with a reference wavelength 650 nm.  The experiments were set up 
as triplicates of each treatment and the data shown as mean ± SD of the optical 
density (OD) values. 
 
Cellular Apoptosis. 
 
Blocking PD-1 and PDL-1 engagement to reverse the HCV core-mediated 
lymphocyte apoptosis was assessed by Annexin V (AV)/Propidium iodide (PI) 
staining (BD Pharmingen).  Briefly, 1 x 106 PBMC were treated with HCV core or 
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β-gal (2 μg/ml; ViroGen) in the presence or absence of anti-PD-1 or anti-PDL-1 
or isotype control antibody (Santa Cruz) for 24 h.  Cell apoptosis was examined 
by FACS using an AV/PI staining kit according to manufacturer’s instructions. 
The primary isotype controls were used to determine the level of background 
staining.  Twenty thousand events were collected after gating on lymphocyte 
populations.   
 
Statistical Analysis. 
 
Data were shown as mean ± SD and level of significance was determined 
using ANOVA as a program of Stata/SE 8.0 software.  P < 0.05 was considered 
significant. 
 
Results 
 
Increased Expression of PD-1 and PDL-1 on CD4+ and CD8+ T Cells of 
Individuals with Chronic HCV Infection. 
 
It has been reported that T cells adapt to persistent antigen exposure by 
down-regulating their responsiveness to TCR signal transduction.  Furthermore, 
recent data suggest a key role for PD-1 in decreasing TCR signaling as a means 
of promoting viral persistence. To determine if PD-1 might be playing a role 
during HCV infection in humans, we examined PD-1 expression on T cells from 
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chronically HCV-infected individuals (n=12) and compared these with T cells from 
healthy donors (n=5).  To this end, peripheral blood mononuclear cells (PBMC) 
isolated from HCV patients and healthy donors were stimulated with or without 
anti-CD3/CD28 antibodies, mimicking the activation of the TCR/CD28 pathway 
by MHC/peptide/B7 complex on T cells.  The cells were harvested at 24 hr after 
the stimulation and the expression of PD-1 on the surface of T cells was 
determined by flow cytometric analysis.  As shown in fig. 2.1A, PD-1 expression 
on the surface of unstimulated (39.02 ± 7.28) as well as anti-CD3/CD28-
stimulated PBMCs (54.01 ± 8.14) isolated from HCV patients is significantly 
higher than the expression observed on the cells of healthy donors (17.88 ± 3.72, 
P=0.002; 36.70 ± 9.17, P=0.005; respectively).  Consistent with the aggregate 
PBMC population data, the expression of PD-1 on the surface of distinct 
subpopulations of CD4+ and CD8+ T cells from HCV patients is also higher than 
that found on healthy donors, with representative dot blots shown in fig. 2.1B.  
The expression of PDL-1 on PBMCs from HCV infected individuals was similarly 
increased, with representative histograms shown in fig. 2.1C.   Treatment with 
other viral proteins, including HCV NS3 as well as HIV Tat and gp120, revealed 
no effect on PD-1 expression levels in PBMC (data not shown). 
It is possible that we started with different lymphocyte phenotype 
subpopulations and that the increases in expression of PD-1 and PDL-1 are 
related to different baseline phenotypes.  Examination of PBMC from two HIV-
infected subjects, however, revealed similar CD45RO+ and CD45RA+ 
subpopulations and increases in expression in PD-1 and PDL-1 upon TCR-
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stimulation (fig. 2.1D)  This is consistent with our hypothesis that HCV infection 
leads to up-regulation of PD-1 and PDL-1 expression via an interaction of HCV 
core with gC1qR that is expressed on multiple T cell phenotypic subpopulations, 
and that there is both HCV-specific and generalized T cell dysfunction in the 
setting of chronic HCV infection. 
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 Figure 2.1  PD-1 expression on PBMCs from chronically HCV-infected individuals is increased 
compared to healthy donors 
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gC1qR-dependent PD-1 and PDL-1 Induction on Healthy T Cells by HCV 
Core Protein. 
 
The above data suggested that PD-1 and PDL-1 are up-regulated in 
response in the setting of chronic HCV infection; how this occurs is unclear, but it 
seems likely that a viral product induces this up-regulation.  Because we have 
previously shown that the HCV core nucleocapsid protein is both necessary and 
sufficient to inhibit T cell responses against viral infection (Yao and others 2001a; 
Yao and others 2001b; Yao and others 2003; Yao and others 2004), we 
examined expression of PD-1 and its ligand, PDL-1, on healthy T cells exposed 
to the HCV core protein.  Peripheral blood mononuclear cells (PBMC) isolated 
from healthy donors were stimulated with or without anti-CD3/CD28 antibodies in 
the presence or absence of HCV core protein.  To confirm that the complement 
pathway is indeed involved in up-regulation of PD-1 signaling, we also treated 
PBMC with C1q protein.  The cells were harvested at 24 hr after treatment and 
the expression of PD-1 and PDL-1 was determined by flow cytometric analysis.  
As shown in fig. 2.2A, treatment of PBMC with C1q leads to an increase in PD-1 
expression compared to control β-gal treatment in unstimulated PBMC;  PDL-1 
expression was also increased in response to C1q treatment (data not shown).  
Both PD-1 and PDL-1 expression can be up-regulated on unstimulated 
lymphocytes exposed to the HCV core protein (from 8% to 12%; and from 27% to 
69%, respectively).  Notably, PD-1 and PDL-1 expression are up-regulated on 
lymphocytes stimulated with anti-CD3/CD28 (from 8% to 20%; and from 27% to 
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70%, respectively), and their expressions can be further up-regulated with HCV 
core treatment (from 20% to 28%; and from 70% to 92%, respectively).  These 
data revealed statistically significant differences.   A titration analysis with HCV 
core protein revealed a dose-dependent increase in PD-1 expression, with 
minimal increases seen at 0.125 μg and saturation by 2 ug/ml of protein (data not 
shown).  Notably, while C1q treatment does appear to up-regulate the PD-1 
pathway, HCV core appears to be more efficient at doing so.  HCV core has, 
however, been shown to have a higher affinity for gC1qR than C1q in previous 
binding studies. 
We next wanted to characterize the expression of PD-1 and PDL-1 on 
specific human T cell subpopulations. PBMCs were treated as above, followed 
by double staining with FITC-anti-human CD4 and PE-anti-human PD-1 and 
PDL-1 conjugates.  As expected based on the data in the aggregate lymphocyte 
population, the expression of PD-1 and PDL-1 are up-regulated by HCV core 
protein on both unstimulated and TCR-activated CD4+ T lymphocytes (fig. 2.2B).  
CD8+ T cells revealed similar trends (data not shown). 
To determine the relationship between HCV core and PD-1 expression, 
we next detected PD-1 mRNA expression in PBMCs stimulated with anti-
CD3/CD28 in the presence or absence of HCV core protein for various times 
after treatment using semi-quantitative RT-PCR.  As shown in fig. 2.2C, PD-1 
mRNA in human cells is consistently up-regulated, starting as early as 6 hrs and 
peaking at 24 hrs after treatment with HCV core protein.  Because we have 
shown that HCV core protein impairs T cell functions through an interaction with 
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the complement receptor, gC1qR, we employed anti-gC1qR antibodies in the 
above experiments and found inhibition of HCV core-induced PD-1 up-regulation.  
This reversal effect can be also achieved by addition of anti-HCV core antibody, 
which interferes with the engagement of core protein with cell surface gC1qR, but 
not by a control serum. To support these findings, healthy, TCR-stimulated 
PBMC were treated with HCV core along with anti-gC1qR or control antibodies 
and PD-1 expression was detected on the surface of healthy CD8+ T cells by 
flow cytometry.  PD-1 expression was diminished in cells treated with antibodies 
to gC1qR, consistent with our PCR data in PBMC.  Notably, treatment of PBMC 
with anti-gC1qR antibodies alone has no effect on either PD-1 expression levels 
as measured by flow cytometry or lymphocyte apoptosis as measured by AV 
staining (data not shown).  These results suggest that HCV core induces PD-1 
expression directly through the gC1qR displayed on the surface of lymphocytes. 
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 Figure 2.2  PD-1 induction on healthy human T cells by HCV core protein 
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Blocking PD-1 and PDL-1 Engagement Restores HCV Core/gC1qR-
Mediated T Cell Dysfunction. 
 
To explore the role of PD-1 and PDL-1 in the HCV core-induced T cell 
dysfunction, we next addressed the possibility of restoring HCV core-mediated 
inhibition of T cell function by blocking PD-1 and PDL-1 engagement.  We have 
previously shown that HCV core modulates T cell activation status, proliferative 
capacity, and apoptosis (Yao and others 2001a; Moorman and others 2003; Yao 
and others 2003; Yao and others 2004). To this end, we incubated TCR-
stimulated healthy PBMCs with HCV core protein in the presence of anti-PD-1 or 
anti-PDL-1 or isotype control antibodies and assayed the above measures of T 
cell function.  We found that treatment of PBMC with anti-PD-1 or anti-PDL-1 
antibodies alone had no effect on any of these measures and found no increase 
in the ability to activate T cells despite blocking PD-1 and PDL-1 signaling (data 
not shown).  We first detected the expression of the T cell activation marker, 
CD69, on the surface of T cells.  As shown in fig. 2.3A, CD69 expression on 
CD4+ and CD8+ T cells was suppressed by exposure to HCV core protein, and 
this suppression was almost totally reversed by the treatment of anti-PD-1 or 
anti-PDL-1 antibody.  CD69 expression on T cells inhibited by HCV core was not 
affected by adding control antibody. 
We next examined T cell proliferation in response to HCV core in the 
presence of antibodies to PD-1 and PDL-1.  We incubated TCR-stimulated 
PBMC with HCV core protein in the presence of anti-PD-1 or anti-PDL-1 or 
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control antibody, and T cell proliferation was evaluated as described in Methods.  
As shown in fig. 2.3B, T cell proliferation was inhibited by HCV core protein, and 
the proliferative ability of T cells inhibited by HCV core could be partially restored 
by simultaneously adding either anti-PD-1 or anti-PDL-1 antibody into the culture.  
These data suggest that the PD-1 pathway plays a role in HCV core-induced T 
cell suppression. 
The induction of cellular apoptosis is one manifestation of HCV core-
mediated T cell dysfunction.  To determine whether blocking PD-1 and/or PDL-1 
engagement can reverse HCV core-induced cell apoptosis, we incubated human 
PBMC with HCV core or control proteins in the presence of anti-PD-1, anti-PDL-
1, or a control antibody for 24 hrs, and apoptosis was evaluated by AV/PI 
staining.  As shown in fig. 2.3C (top), HCV core induces apoptosis, as 
represented by increasing percentages of AV/PI positive cells, when compared 
with those treated with a control protein, β-gal; this core-induced cell apoptosis 
can be successfully blocked by the treatment with either anti-PD-1 or anti-PDL-1 
antibody.  These data are reproducible in multiple independent experiments 
(bottom). 
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 Figure 2.3  Blocking PD-1 and PDL-1 engagement inhibits HCV core/gC1qR-mediated T cell 
dysfunction 
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Discussion 
 
The most enigmatic facet of HCV infection is the fact that the majority of 
individuals infected with this virus exhibit impaired T cell responses and develop 
persistent infection, while a limited group are able to successfully control their 
infections and experience spontaneous virus eradication.   It is generally agreed 
that both viral and host factors play a role in determining the outcome of viral 
infection.  Our previous studies (Yao and others 2001a; Moorman and others 
2003; Yao and others 2003; Yao and others 2004) and current data would 
suggest that HCV core protein may be a major viral antigen involved in 
immunomodulating host responses. Intriguingly, HCV core is secreted from 
infected cells and circulates in the bloodstream of infected individuals (Masalova 
and others 1998; Maillard and others 2001) at levels consistent to those used in 
our experiments.  In addition, the amount of free core protein or core protein 
expressed on the surface of infected cells is greater in the micro-environment of 
the liver, where virus replication occurs quite vigorously in early infection when 
chronicity is either avoided or established.  Thus, HCV core protein appears to be 
available in the setting of clinical infection and based on our studies could be 
contributing to establishment of persistent HCV disease. 
While it seems clear that HCV evades relatively weak host immune 
responses, the issue of the level and specificity of immunosuppression in 
individuals with HCV infection remains debatable.  Several reports suggest that 
selective dysfunction of HCV-specific T cells occurs in HCV-infected patients, 
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with preservation of immune responses to unrelated viruses and/or antigens 
(Gruner and others 2000; Takaki and others 2000; Thimme and others 2001; 
Wedemeyer and others 2002).  Other studies, however, have found 
abnormalities with T cell responses to unrelated or nonspecific antigens in the 
setting of HCV infection. For example, CMV-specific CD8+ maturation markers 
were dramatically lost in an HCV-infected cohort despite the fact that inducible 
responses to antigen were preserved (Lucas and others 2004).  This study 
suggested that HCV infection had a pervasive effect on numerous CD8+ T cell 
populations and not merely HCV-specific T cells.  Interestingly, a recent study in 
an HIV/HCV co-infected cohort found that IFNγ secretion to recall antigens 
including Candida (as well as HCV antigens) correlated with the degree of 
hepatic fibrosis, with the data suggesting that impaired cellular responses were a 
qualitative defect rather than a function of CD4 cell count (Graham and others 
2005).  It is by no means impossible that both HCV-specific and non-specific 
immunodysregulatory mechanisms are occurring during acute and chronic HCV 
infection, perhaps supported by the strong clinical evidence of autoimmune 
disease associated with HCV infection (Manns and Rambusch 1999; Vogel and 
others 2002). 
Our data would support nonspecific immunomodulation of both CD4+ and 
CD8+ T cell functions by HCV core antigen.  We have in this and previous studies 
consistently noted effects on T cell proliferation, activation, and apoptosis in 
response to HCV core and dependent upon gC1qR engagement (Yao and others 
2001a; Moorman and others 2003; Yao and others 2003; Yao and others 2004).  
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This does not rule out the presence of HCV-specific T cell dysfunction by HCV 
core or other viral gene products, and certainly further studies in this area are 
warranted.  It is also feasible that HCV core expression in the peripheral blood of 
infected patients, while perhaps not sufficient to induce the severe, generalized 
immunosuppression seen with HIV, may be high enough to reach a threshold 
locally in the liver to facilitate persistent HCV infection. 
The novel role of PD-1 and PDL-1 in HCV described herein is exciting and 
may ultimately provide a marker and perhaps a mechanism by which such 
viruses establish persistent infection.  The recent studies of LCMV infection in a 
murine model and HIV in humans clearly demonstrate a key role for PD-1 up-
regulation in CD8+ T cell exhaustion and control of viral infection (Barber and 
others 2006; Day and others 2006; Freeman and others 2006; Petrovas and 
others 2006; Trautmann and others 2006b).  Our data in human T cells suggest 
that that HCV might function in a similar model, with up-regulation of PD-1 being 
associated with and perhaps contributing to chronicity.  While it is certainly 
possible that this up-regulation of PD-1 in chronically HCV-infected individuals is 
more a marker of chronicity, there is little doubt that signaling via this pathway in 
general leads to immunomodulation (Nishimura and Honjo 2001).  We expect 
that other chronic viruses may be associated with PD-1 up-regulation as well. 
Once again, our data would suggest that up-regulation of the PD-1 and 
PDL-1 pathway occurs in the general T cell population, but it would clearly be 
worth pursuing an analysis of PD-1 expression in HCV-specific CD8+ and CD4+ T 
cell populations from chronically infected individuals using tetramer studies and 
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antibodies to PD-1 and PDL-1.  Complicating these studies is the very real 
technical challenge of analyzing virus-specific T cells that are often absent or 
present at very low frequencies in individuals with chronic HCV infection (He and 
others 1999); studies in this area are in progress but reversal of virus-specific T 
cell dysfunction thus far has not been accomplished.  It is possible that core-
induced up-regulation of PD-1 and PDL-1 might be occurring on antigen 
presenting cells or hepatic tissues and promoting T cell dysfunction through cell-
cell interaction. 
Our data demonstrated the ability to reverse T cell dysfunction in healthy 
donor PBMCs exposed to HCV core by blocking PD-1 engagement, supporting a 
link between HCV core, gC1qR, PD-1, and T cell functions.  Whether this 
reversal can occur in chronically infected HCV-infected individuals is no doubt 
the most pressing question, but has thus far been technically challenging for us 
to determine in infected individuals in the setting of years of chronic antigen 
exposure and T cell anergy. The intracellular mechanism(s) linking these 
pathways are also as yet unclear, but possibilities include SHP-1/2 or the SOCS 
family that have been linked to negative regulation of T cell signaling pathways 
(Balasubramanian and others 2003; Bode and others 2003).  Studies addressing 
these questions are ongoing. 
We have thus found up-regulation of the PD-1 pathway in chronically 
infected individuals with HCV that may be mediated through HCV core protein, a 
known immunomodulatory viral antigen that circulates in the serum of infected 
individuals.  This study raises the possibility of targeting this inhibitory pathway 
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for the treatment of persistent viral infections.  Blocking either the gC1qR or PD-1 
inhibitory pathways might be of clinical benefit during the acute phase of viral 
infection when persistence is established in the majority of hosts.  Restoring 
impaired T cell function during chronic infection, albeit challenging, may be the 
more desirable goal.  This might be achievable based on limited evidence of 
occasional resolution of HCV infection with increasing CD4+ T cell numbers and 
function following HAART for HIV infection. Furthermore, the most common 
reason for failure of therapeutic vaccine in eliminating chronic diseases is limited 
T cell proliferative potential, and as such a better understanding of this novel 
mechanism by which viruses impair T cell responses may open new avenues for 
immunotherapy by inhibition of fundamental, negative regulatory pathways.   
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Figure Legends 
 
Figure 2.1  PD-1 Expression on PBMCs from Chronically HCV-infected 
Individuals is Increased Compared to Healthy Donors.   
 
A)  PMBC were isolated from 12 chronically HCV-infected patients 
(circles) and 5 healthy donors (squares).  The cells were stimulated with (filled 
circles or squares) or without anti-CD3/CD28 (anti-TCR stimulation, open circles 
or squares) for 24 h, and PD-1 expression on lymphocytes was examined as 
described in Materials and Methods.  Percentage of PD-1+ cells in the gated 
lymphocyte population was shown.  Statistical comparison (p values) amongst 
different groups, including PD-1 expression on T cells from chronic HCV patients 
versus healthy donors as well as unstimulated cells versus TCR-stimulated cells, 
are all < 0.01.  Data represent cumulative results of three independent 
experiments.  B) Representative dot blots from subjects showing percentages of 
PD-1+ cells in the TCR-stimulated CD4+ and CD8+ T lymphocyte populations.  
Lymphocytes were double-stained and gating was performed on distinct 
populations of either CD4+ or CD8+ cells.  Isotype controls for these experiments 
are shown.  C) Representative histograms of PDL-1 expression on unstimulated 
lymphocytes from HCV-infected or healthy subjects. D) PD-1 and PDL-1 
expression on different PBMC phenotype populations. PBMC from 2 chronic 
HCV patients were subjected to mock stimulation or TCR-activation and PD-1 
and PDL-1 expression on CD45RA+ and CD45RO+ populations were detected by 
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flow cytometric analysis.  Percentages of PD-1 and PDL-1 on CD45RA+ and 
CD45RO+ lymphocytes are shown on the upper right corner. 
  
Figure 2.2  PD-1 Induction on Healthy Human T Cells by HCV Core 
Protein.  
 
  A) PD-1 induction on lymphocytes by C1q protein and HCV core protein. 
Left, unstimulated PBMC from healthy donors were exposed to C1q or a control 
protein β-gal for 24 hr, and PD-1 expression on the surface of the treated 
lymphocytes was examined as described in Methods.  The percentages of PD-1 
expression on lymphocytes are shown and the data are representative of 
experiments from two separate donors.  Middle and right, unstimulated or TCR-
stimulated PBMC from healthy donors were exposed to HCV core or a control 
protein β-gal for 24 h, and PD-1 and PDL-1 expressions on the surface of the 
treated lymphocytes were examined as described in Methods.  The percentages 
of PD-1 or PDL-1 expression on PBMCs are shown and are representative of 
three independent experiments. Cumulative analysis of these experiments 
revealed statistical significance between β-gal- and β-gal core-treated 
unstimulated cells and stimulated cells (unstimulated PD-1:  10.09 ± 2.7 vs 16.5 
± 5.03, p<0.05; stimulated PD-1:  18.05 ± 2.9 vs 32.15 ± 5.3, p<0.05; 
unstimulated PDL-1:  31.27 ± 19.98 vs 58.60 ± 16.03, p<0.05; stimulated PDL-1:  
65.9 ± 5.6 vs 90.75 ±2.3, p<0.02).  B) PD-1 and PDL-1 induction on the CD4+ T 
cell subpopulation by HCV core protein.  Unstimulated or TCR-stimulated PBMC 
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from healthy donors were exposed to HCV core or control protein β-gal for 24 h, 
and PD-1 and PDL-1 expression on the surface of the treated CD4+ T 
lymphocytes were examined as described in Methods.  Cells were double-
stained and gating was performed on a distinct CD4+ population; data shown are 
representative dot blots from three independent experiments.  The percentages 
of PD-1 or PDL-1 expression on CD4+ T lymphocytes are shown.  C) Time- and 
gC1qR-dependent PD-1 mRNA induction by HCV core protein.  Above, TCR-
activated PBMC were treated with or without HCV core in the presence or 
absence of anti-HCV core, anti-gC1qR or a control antibody for various time 
points and PD-1 expression was detected by semi-quantitative RT-PCR as 
described in the Methods.  β-actin serves as a control.  Results are 
representative of two independent experiments.  Below, flow cytometric analysis 
of gC1qR-dependent PD-1 induction on CD8+ T cells by HCV core protein.  
PBMC from 2 healthy donors were TCR-stimulated and treated with HCV core in 
the presence or absence of anti-gC1qR or a control antibody for 24 hr, and PD-1 
expression on CD8 + T cells was analyzed by flow cytometry.  Percentage of PD-
1+ cells in the CD8+ populations is shown on the upper right corner. 
 
Figure 2.3  Blocking PD-1 and PDL-1 Engagement Inhibits HCV 
Core/gC1qR-mediated T Cell Dysfunction.   
 
A) Blocking PD-1 pathway signaling restores the expression of the early T 
cell activation marker CD69 that is inhibited by HCV core.  PBMC were 
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stimulated with anti-CD3/CD28 in the presence of HCV core or control protein β-
gal for 24 h.  Anti-PD-1 or anti-PDL-1 antibody was added to the TCR-stimulated 
and core-treated cells simultaneously.  T cell activation was assessed by 
detecting CD69 expression on the surface of CD4+ and CD8+ T lymphocytes as 
described in Methods.  Isotype controls for staining are shown.  Results are 
representative of two independent experiments with separate donors.  In the 
CD4+ subpopulation, statistical significance was observed between β-gal and β-
gal-core-treated cells (55.6 ± 3.7 vs 13.2 ± 2.7, p<0.01), between β-gal-core-
treated cells and β-gal-core-treated cells with antibody to PD-1 (41.5 ± 11.1 vs 
13.2 ± 2.7, p<0.04), and between β-gal-core-treated cells and β-gal-core-treated 
cells with antibody to PDL-1 (57 ± 8.1 vs 13.2 ± 2.7, p<0.01).  B) Blocking PD-1 
pathway prevents HCV core-induced inhibition of T cell proliferation.  PBMC were 
stimulated with or without anti-CD3/CD28 in the presence or absence of HCV 
core protein for 24 h.  Anti-PD-1 or anti-PDL-1 antibody was added to the TCR-
stimulated and core-treated cells simultaneously.  T cell proliferation was 
assessed by Quick Cell proliferation assay.  Statistical significance is shown and 
results are derived from three independent experiments with separate donors.  
C) Blocking PD-1 pathway prevents HCV core-induced T cell apoptosis.  PBMC 
were TCR-stimulated in the presence or absence of HCV core protein for 24 h.  
Anti-PD-1 or anti-PDL-1 antibody was added to the TCR-stimulated and core-
treated cells simultaneously.  T cell apoptosis was assessed by AV/PI staining as 
described in Methods.  Above, percentages of cells in the early apoptotic stage 
(only AV positive) and in death (AV/PI double positive) after the treatment are 
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shown.  Below, the data were shown as percentage of cells positive for AV or PI 
(mean ± SD) on the gated T cell populations from six independent experiments 
with separate donors.   * denotes statistical significance when compared to 
control treatment (p<0.01).   †denotes statistical significance when compared to 
HCV core treatment (p<0.01). 
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CHAPTER 3 
 
Hepatitis C:  the Complications of Immune Dysfunction 
 
Summary
 
Hepatitis C virus (HCV) infection has been linked to numerous diseases of 
immune dysfunction, including but not limited to essential mixed cryoglobulinemia 
and non-Hodgkin’s lymphoma. Clinical studies support these associations and 
treatment of the underlying HCV infection has been variably successful.  Recent 
studies focusing on the role of HCV gene products have discovered evidence of 
dysregulated responses in multiple aspects of host immunity that may be 
contributing to the genesis of these diseases.  Novel treatments that target these 
areas of dysregulation offer hope for improved therapy for the diseases 
associated with immunodysregulation by HCV.  
 
Introduction 
 
 HCV was identified as the agent of transfusion related non-A, non-B 
hepatitis in 1989 (Choo and others 1989).  The Centers for Disease Control and 
Prevention estimate 2.7 million Americans have chronic hepatitis C infection with 
an annual monetary cost (medical and work loss) of >600 million dollars.  The 
majority of acute cases occur in adults 30-49 years old and HCV infection is the 
leading indicator for liver transplant in the U.S. and Europe (Alter and others 
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1997; Hoofnagle 1997).  Persons who have chronic hepatitis C infection are at 
significant risk of developing cirrhosis, hepatocellular carcinoma and notably 
diseases of immune dysfunction, including essential mixed cryoglobulinemia and 
lymphoproliferative disorders (Hoofnagle 1997), upon which this review will 
focus.  Disease progression varies greatly from person to person, making it not 
only difficult to predict who will develop chronic disease but also which of the 
chronically infected will go on to develop significant sequelae.  To further 
compound the issue, it appears that the six major genotypes described may have 
differing disease patterns and responses to treatment (Simmonds and others 
1993b). 
 Hepatitis C is a 9.5-kb, positive strand, RNA virus of the Flaviviridae 
family.  The genome consists of ~9500 nucleotides encoding a single polyprotein 
of ~3000 amino acids that is cleaved into structural and non-structural proteins.  
It encodes three structural proteins (core, E1 and E2) and at least six non-
structural proteins (Figure 3.1).   
Figure 3.1 HCV genomic structure
HCV is classified into 6 genotypes with over 30 subtypes based on sequence 
variation in the core and E1 genes, additionally, there are significant 
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geographical variations (Simmonds and others 1993b).  Persons with long-term 
infections tend to have greater levels of genetic diversity within their genotypes 
(quasispecies) (Farci and others 1997), most likely due to the poor fidelity of the 
HCV RNA polymerase.  The phenomena of high levels of quasispecies is 
associated with poor clinical prognosis, which may be linked to the poor cytotoxic 
lymphocyte (CTL) response in chronically infected persons. 
In the U.S., HCV genotypes 1a and 1b are most prevalent and the most 
resistant to the currently available therapy, pegylated interferon-α (IFN-α) and 
ribavirin (Hoofnagle 2003).  This combination treatment will induce a sustained 
virologic response (SVR) in 42-48% of persons infected with genotype 1a or 1b 
but up to 76-88% of persons infected with genotypes 2 or 3 (Fried and others 
2002).  Side-effects, however, are common and can be serious.  For example, 
IFN-α is associated with significant depression and ribavirin can induce anemia 
and neutropenia and is teratogenic.   
 The study of HCV is made difficult by two key factors.  HCV will only 
reliably infect humans and chimpanzees, thus limiting animal models, and in vitro 
replication is very poor (although some replicon systems have been functional in 
hepatocytes.)  Since newly infected persons are often asymptomatic and 
therefore are rarely clinically recognized as infected, it has also been difficult to 
determine the initial immune responses that correlate with viral clearance.  
Finally, because diseases associated with immune dysfunction occur frequently 
in individuals without HCV infection, it has been difficult to confirm strong 
associations between HCV and a given disease.  This review will describe the 
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common diseases of immune dysfunction associated with HCV infection and 
discuss potential mechanisms underlying these diseases. 
 
Potential Mechanisms of HCV-mediated Immune Dysfunction 
While the precise mechanisms for how the disruption of the host immune 
response by HCV can result in various immune disorders have yet to be defined, 
it is apparent that HCV modulates host immunity on several different levels 
(Moorman and others 2001b).  Over the past decade, there have been numerous 
studies examining different facets of HCV-associated immune dysfunction which 
have included B-cell, T-cell, NK cell, and dendritic cell dysregulation (Figure 3.2).  
The significance of such immunomodulatory potential appears to be twofold: 
evasion of the host immune response leading to viral chronicity, and the potential 
for development of lymphoproliferative disorders.  
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  Figure 3.2  Proposed model for immune dysregulation by HCV infection 
It is noteworthy that HCV clearly infects multiple extrahepatic cell types, 
including peripheral blood mononuclear cells, and this is observed both in vivo 
and in vitro (Shimizu and others 1992; Shimizu and others 1997; Lerat and 
others 1998; Radkowski and others 2000; Radkowski and others 2002; Nowicki 
and others 2005).  It is therefore possible that the immune dysfunction observed 
in HCV is a function of its ability to infect such cells, although the frequency of 
this infection appears low.  HCV sequences observed in different cellular 
compartments and in particular peripheral blood mononuclear cells may vary, 
suggesting viral tropism for specific cells that may be in part affected by the HCV 
diversity that occurs as quasispecies develop (Lerat and others 1998).  The role 
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of a given genotype in targeting hematopoetic cells remains controversial (Kao 
and others 1997; Lerat and others 1998). 
 
Dysregulation of B Cell Function Mediated by HCV 
Since the association between chronic HCV infection and both mixed 
cryoglobulinemia and B-cell lymphoma was first recognized, there have been an 
increasing number of studies examining B cell dysfunction in the context of 
chronic HCV infection.  While it has clearly been shown that clonal populations of 
B lymphocytes are disproportionately present in increased numbers in patients 
with chronic HCV infection, there are also numerous data detailing specific 
mechanisms behind B cell clonality.  Moreover, such mechanisms offer insight 
into the presence of immune dysfunction in patients with chronic HCV infection.  
Most notably, B cells have become a target of drug development for the 
treatment of certain HCV-associated immune diseases (Kazkaz and Isenberg 
2004). 
Franzin et al. were the first to report the presence of clonal B cell 
expansion in the peripheral blood of 38 HCV-infected patients (Franzin and 
others 1995). Subset analyses in their study revealed the presence of clonal 
immunoglobulin gene rearrangements in 100% of HCV-positive patients with type 
II mixed cryoglobulinemia (MC) as opposed to only 24% of HCV-positive patients 
without mixed cryoglobulinemia. The reversibility of B cell clonality in chronic 
HCV infection was similarly assessed in a cohort of 20 patients with HCV-
associated MC undergoing interferon-α therapy (Mazzaro and others 1996).  
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While 80% of these patients (all of whom were noted to have clonal populations 
of B cells) achieved complete or partial clinical responses, 15% reverted to 
polyclonal B cell populations following therapy.  Recent studies also suggest 
upregulation of B-lymphocyte stimulator (BLyS) in the setting of MC (Fabris and 
others 2006; Sene and others 2006), further supporting a significant relationship 
between clonal expansion of B lymphocytes and HCV-associated mixed 
cryoglobulinemia.  Zignego et al. found an increased frequency of bcl-2 gene 
rearrangement(t(14;18) in a prospective study of individuals with HCV and mixed 
cryoglobulinemia (Zignego and others 2002), described in detail below. While 
Toubi et al. observed enhanced B cell apoptosis in B cells from chronically 
infected HCV patients, there was relative resistance to apoptosis seen in the 
CD95/Fas+ B cell subpopulation, suggesting a potential role for this 
subpopulation in B cell proliferative disorders (Toubi and others 2004). 
As the propensity of HCV to induce lymphoproliferation in patients with 
HCV-associated mixed cryoglobulinemia has been further elucidated, there has 
been some effort to define the underlying mechanisms.  Machida et al. reported 
that an HCV E2-CD81 interaction modulates host B cell responses by enhancing 
activation-induced cytidine deaminase (AID) and hypermutating V(H) 
immunoglobulin genes in B cells, suggesting a mechanism for HCV-associated B 
cell lymphoproliferative disorders (Machida and others 2005).  HCV E2 was also 
shown to activate the JNK pathway leading to preferential proliferation of CD27+ 
B cells (Rosa and others 2005).   
The effect of HCV core protein on molecular profiling in human B-
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lymphocytes was recently examined by Wu et al., who found dramatic evidence 
of inhibition of B lymphocyte apoptosis by HCV core in several steps of the 
apoptotic cascade (Wu and others 2006). The investigators expressed HCV core 
in an adenoviral vector in a healthy population of human B lymphocytes and 
observed downregulation of MHC class II molecules, and caspase-1 and -4, 
which are proapoptotic proteins; as well as upregulation of nuclear factor of κ 
light peptide inhibitor gene and TATA box protein, both of which are associated 
with B cell lymphoma.  Similarly, we have very recently found a differential 
response of B cells and T cells to HCV core protein, with upregulation of B cell 
functions (immunoglobulin expression and cell proliferation) and inhibition of B 
cell apoptosis in the setting of downregulated T cell responses (personal 
communication, JPM).  These findings underscore the potential of HCV to disrupt 
antigen presentation and apoptosis and may indicate yet another mechanism for 
HCV-related autoimmunity and lymphoproliferation. 
Oncogenes have also been a focus of investigation in patients with MC.  
In a prospective study of 37 patients with HCV-associated mixed 
cryoglobulinemia, Zignego et al. found that 75.7% had bcl-2 rearrangement in 
peripheral blood mononuclear cells, as opposed to 37.6% of patients with chronic 
HCV infection without mixed cryoglobulinemia (Zignego and others 2002). Galli-
Stampino et al. further expanded on the relationship between oncogenesis and 
clonal B cell expansion in patients with HCV-associated mixed cryoglobulinemia 
by demonstrating the presence of restricted V(H)I gene sequences in peripheral 
blood, hepatic, and lymph node B lymphocytes in three of four patients (Galli-
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Stampino and others 2003). These gene sequences are usually associated with 
B-cell non-Hodgkin’s lymphoma and their presence in patients with chronic HCV 
patients may indicate a mechanism of developing NHL through non-malignant, 
clonally expanded B-cell populations. 
 
Type I Interferon Dysregulation 
Interferon-α (IFN-α) stimulation is a critical and non-specific response to 
viral infection.  Its two main effects are induction of an anti-viral state in infected 
cells and interferon receptor ligation which results in activation of Janus kinase 
(Jak) and signal transducer and activator of transcription (STAT).  Jak/STAT 
signaling in turn activates numerous interferon-response genes including 2’-5’ 
oligoadenylate synthetase (OAS), Mx proteins and the double-stranded RNA 
dependent protein kinase (PKR) (Katze 2002).  PKR is induced by double 
stranded viral RNA and in-turn, phosphorylates eukaryotic initiation factor 2 (elF-
2), resulting in inhibition of cellular protein syntheses and viral replication.  Two 
HCV proteins, the envelope glycoprotein E2 and the nonstructural protein NS5A, 
have been reported as potential inhibitors of the IFN response (Taylor 2000; 
Pflugheber and others 2002).  
Phosphorylated interferon factor 3 (pIRF-3) is the key transcription factor 
for type I interferon (Foy and others 2003).  Type I interferon in turn, upregulates 
the expression of PKR.  Recently, the HCV protein NS3/4A (a serine protease) 
was shown to interrupt the IFN signaling pathway; thus, IRF-3 is never 
phosphorylated and IFN production is not induced (Foy and others 2003).  The 
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importance of IRF-3 was also demonstrated with mutations resulting in dominant 
negative or constitutively active IRF-3 leading to enhanced or restrained HCV 
replication, respectively. 
 
Dysregulation of the NK Response 
Natural killer (NK) cells play a critical role in innate immunity.  NK cells 
mediate lysis of target cells by releasing cytotoxic granules which contain perforin 
and granzymes or by binding apoptosis inducing receptors on the target cells.  
NK cells also secrete numerous cytokines including IFN-γ and TNF-α during 
inflammation (Poccia and others 2001).  Recent reports have implicated the HCV 
E2 protein in suppression of NK activity (Crotta and others 2002; Tseng and 
Klimpel 2002). 
The HCV E2 protein binds CD81 which is expressed on the surface of 
host cells.  When NK cells are exposed to immobilized E2 or anti-CD81 (in vitro), 
their function is impaired.  The impairment ranges from suppressing of 
cytotoxicity and IL-2 induced proliferation to suppressing IL-2, IL-12 and IL-15 
induction of IFN-γ (Crotta and others 2002; Tseng and Klimpel 2002).  
Additionally, ligation of CD81 inhibits CD16-mediated activation of extracellular 
signal-regulated kinase (ERK) and mitogen-activated protein kinase (MAPK) in 
NK cells (Crotta and others 2002).  These mechanisms, if employed by HCV, 
could facilitate HCV persistence.  However this possibility needs further research 
as NK cells do not play a role in all viral infections. 
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Dysregulation of Dendritic Cells by HCV Envelope Glycoproteins 
One possible cause of an impaired CD8+ response to HCV infection may 
be abnormal dendritic cell (DC) function preventing appropriate antigen 
processing and presentation.  Interestingly, HCV E1 and E2 glycoproteins 
interact with DC-specific intercellular adhesion molecule 3 (ICAM-3), grabbing 
nonintegrin (DC-SIGN) and its receptor, DC-SIGNR in immature DCs (Lozach 
and others 2003; Pohlmann and others 2003).  The role of HCV interactions with 
DC remains controversial.  Numerous studies demonstrate abnormal DC activity 
in chronic HCV patients, yet recent studies by Longman et al. report the converse 
(Longman and others 2005). 
In addition to envelope proteins, HCV core has also been implicated in 
inhibiting DC and macrophage function (Sarobe and others 2003).  Addition of 
extracellular core or expression of core/E1 in mice by recombinant adenovirus 
demonstrated an effect on DC maturation and T cell responses upon allogenic 
stimulation.  A molecular mechanism(s) has not fully elucidated to explain this 
inhibition. 
 
Dysregulation of T Cell Function Mediated by HCV Core Protein 
Patients who have a strong and broad cytotoxic lymphocyte (CTL) 
response are more likely to spontaneous resolve a HCV infection when 
compared to those with a weaker response (Lechner and others 2000).  The CTL 
response is suppressed during all phases of HCV infection, although the 
suppression mechanism(s) are not well understood.  One hypothesis for weaker 
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CTL responses is that the HCV proteins interact either directly or indirectly 
against CTLs.  Data have been published indicating that HCV core antagonizes 
host T cell responses, thus potentially contributing to disease progression (Large 
and others 1999b; Ray and Ray 2001).   
 HCV core appears to interact with at least two major cellular signaling 
pathways:  intracellular core interacts with tumor necrosis factor receptor (TNFR) 
and Fas, and extracellular core interacts with the complement receptor gC1qR 
(Kittlesen and others 2000).  Interactions between core and TNFR or Fas are 
known to induce apoptosis in both hepatocytes and lymphocytes, suggesting a 
possible mechanism for HCV-associated liver pathology (Hahn and others 2000; 
Zhu and others 2001; Moorman and others 2003).  However, whether the liver 
pathology results from core-induced apoptotic hepatocytes or is a secondary 
necrosis induced by infiltration of apoptotic lymphocytes remains to be 
determined.   
 Intracellular core appears to localize to the cytoplasm, ER and nucleus, 
while extracellular core is found in transfected cell lines and in the serum of 
infected patients (Sabile and others 1999; Maillard and others 2004).  This same 
extracellular core has also been found to interact with the complement receptor 
gC1qR, which results is inhibition of T cell activity (Kittlesen and others 2000).  
This inhibition appears to take place early in infection and targets T cell 
proliferation and IFN-γ production (Yao and others 2001a).  C1q, the natural 
ligand for gC1qR, is part of the C1 complex and is the first component in the 
classical complement pathway.  C1q, like HCV core, will also inhibit T cell 
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proliferation, suggesting that core may usurp this pathway to its advantage.  
Other viruses such as Epstein Barr and HIV appear to exhibit similar 
mechanisms to suppress the host immune response by interactions with the 
complement system (Hilleman 2004).   
 While HCV core appears to be a useful target as an antigenic stimulus 
because of its highly conserved nature, this protein has also been associated 
with the development of auto-antibodies such as anti-LKM, anti-p450, and anti-
GOR.  Interestingly, alteration of core antigen to remove the molecular mimic 
sites responsible for induction of these auto-antibodies was recently used to elicit 
strong antigen-specific CTL responses with less self-recognition (Liu and others 
2006).   
 
HCV and the Associated Clinical Diseases of Immune Dysfunction 
 At least 36 extrahepatic disease manifestations have been associated with 
HCV infection, with disorders of immune function frequently described (Table 
3.1).  With the exception of mixed cryoglobulinemia, acceptance of other disease 
associations with HCV infection is not universal (Agnello 1997), but many have 
fairly strong anecdotal support in the literature.  While the data linking HCV 
infection with non-Hodgkins lymphoma (NHL) is strong, the mechanism(s) 
underlying the association remain poorly understood (Gisbert and others 2003).   
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Table 3.1 Extrahepatic disease manifestations associated with HCV infection 
Antiphospholipid syndrome MALToma 
Aplastic anemia Membranoproliferative glomerulonepritis*
Autoimmune hemolytic anemia Membranous glomerulonephritis 
Autoimmune thyroiditis Mixed cryoglobulinemia* 
Chronic fatigue syndrome Moorne corneal ulcers 
Behcet’s syndrome Multiple myeloma 
Carotid atherosclerosis Non-Hodgkin’s lymphoma (NHL)* 
CREST syndrome Neurocognitive impairment 
Dermatomyositis Pancreatitis 
Diabetes mellitus Polyarteritis nodosa 
Fibromyalgia Polymyositis 
Guillain-Barre syndrome Phophyria cutanea tarda 
Hypertrophic cardiomyopathy Rheumation arthritis 
Hypocholesterolemia Sialadenitis 
Idiopathic pulmonary fibrosis Sjogren’s syndrome 
Idopathic thrombocytopenia purpura Systemic lupus erythematosus 
IgA deficiency Uveitis 
Lichen planus Waldenstrom’s macroglobulinemia 
*Presented in greater detail in the text. 
CREST: calcinosis Cutis, Raynaud’s phenomenon, esophageal dysfunction, sclerodactyly and 
telangiectasia; HCV: Hepatitis C infection; MALT: Mucosa-associated lymphoid tissue 
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Mixed Cryoglobulinemia (Type II Cryoglobulinemia) 
 
Disease. 
 
Cryoglobulinemia is defined as the presence of circulating 
immunoglobulins (Ig) that reversibly precipitate at <37°C.  The term “mixed 
cryoglobulins” was coined to differentiate types II and III, which is characterized 
by a mixture of 2 different kinds of antibodies, from type I, characterized by just a 
single monoclonal antibody.  Cryoglobulins may precipitate in vivo in small blood 
vessels (venules, capillaries, arterioles), leading to vasculitis.  The evidence 
linking HCV and mixed cryoglobulinemia (MC) is strong and is supported by 
epidemiological, molecular, and virological studies. 
 
Prevalence. 
 
In the early 1990s, multiple investigators reported the presence of HCV 
infection in 50-90% of MC patients (Ferri and others 1991; Agnello 1997).  The 
frequency of dual status exhibits geographic variation, with southern Europe 
having a higher rate than northern Europe or North America (Cacoub and others 
2000).  The most likely explanation for this difference is differing laboratory 
techniques used to identify cryoglobulins.  This hypothesis is supported by the 
fact that regions that reported a higher frequency of HCV with MC generally used 
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more sensitive laboratory methods to identify MC and consistent use of these 
more sensitive methods has revealed increasing prevalence rates over time. 
 One alternative to using the more sensitive methods for detecting 
cryoglobulins is to test for rheumatoid factor (RF).  RF displays a high avidity for 
IgG and thus easily forms immune complexes.  Common tests for RF are 
generally much more sensitive than tests for cryoglobulins.  This was 
demonstrated when data from 408 patients infected with HCV revealed that 40% 
were positive for cryoglobulins, yet 100% were positive for RF (Karlsberg and 
others 1995).  HCV is now linked to approximately 73% of all forms of 
cryoglobulinemia (Trejo and others 2001).  Notably, the presence of 
cryoglobulinemia is highly associated not only with extrahepatic disease, as 
described below, but also with the development of cirrhosis (Kayali and others 
2002). 
 
Clinical Manifestations. 
 
Traditionally, the presence of purpura, arthralgias, and weakness were 
used to diagnose MC; this is no longer adequate as other symptoms are now 
known to be associated with MC as well (Table 3.2) (Mayo 2003).  Many persons 
with detectable cryoglobulins display no obvious symptoms.  When present, the 
classic skin rash is a palpable purpura that may rarely progress to a necrotizing 
lesion or systemic vasculitis.  Arthralgias are a common complaint of persons 
with MC and most often affect the proximal interphalangeal joints, 
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metacarpophalangeal joints, and knees.  In some cases, exposure to cold 
temperatures will increase the pain and stiffness in these areas.  Changes in 
renal function and peripheral neuropathies are also more common than 
previously thought. 
Table 3.2 Symptoms of cryoglobulinemia  
Symptom Incidence 
Skin disease 22% 
Joint disease 16% 
Weakness 65% 
Renal disease 25-30% 
Raynaud phenomenon 3-50% 
Neuropathy 8-25% 
Sicca syndrome 20% 
Lymphadenopathy 3% 
Fever 3% 
Adapted from:  (Dickson 1997; Hoofnagle 1997; Lunel and Musset 2001; Schott and others 2001; Raanani 
and Ben-Bassat 2002; Mohammed and Rehman 2003; Nocente and others 2003; Han 2004; Ramos-Casals 
and Font 2005; Vassilopoulos and Calabrese 2005; Vigani and others 2005) 
 
Notable differences are observed when HCV-associated MC (HCV-MC) 
patients are compared to MC patients without HCV infection.  Both groups 
display the same frequency of cutaneous involvement, renal involvement and 
peripheral neuropathy, but the HCV-MC patients are less likely to manifest fever, 
lymphadenopathy, articular involvement, or Raynaud’s phenomenon.  ANA and 
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RF are common in both groups, but MC patients without HCV are more likely to 
have ANA, whereas HCV-MC patients are more likely to have RF (Trejo and 
others 2001).  Circulating immune complexes will activate complement and 
therefore low levels of C3, C4, and CH50 are seen in all patients with MC.  
However, the levels of C4 and CH50 are significantly lower in HCV-MC versus 
non-HCV-MC patients (Trejo and others 2001). 
 
Pathogenesis. 
 
The symptoms of MC are due the vascular deposition of the 
cryoprecipitate, which contains HCV-RNA, LDL, VLDL, IgG and monoclonal IgM 
that has RF activity; these deposits can then lead to vasculitis.  The importance 
of HCV infection in this process is demonstrated by the increased levels of virus 
and RF antibody (up to 1000 fold higher) at the site of vascular lesions when 
compared to serum levels (Agnello and others 1992).  Persons with HCV-MC can 
also present with abnormal B cell proliferation, as described in detail above, 
which appears to be an antigen driven process that can ultimately result in a 
dominant B cell clone.  This may be the result of genetic mutation; for example, 
88% of patients who are HCV-MC demonstrate a translocation of the bcl-2 gene 
from chromosome 18 to chromosome 14, compared to 8% of patients with HCV 
alone and 2% of patients with other liver diseases (Zignego and others 2002).  
However, translocation has not been shown to be a definitive cause, since bcl-2 
overexpression does not always accompany t(14;18) translocation 
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(Papakonstantinou and others 2001).  B cells with the t(14:18) translocation 
without bcl-2 overexpression and mRF B cells that over express bcl-2 without the 
t(14:18) translocation may be present in the blood.  The two populations cannot 
be discerned without isolation studies that thus far have not been performed. 
 
Management 
 
Prior to the recognition that HCV is associated with MC, plasmapheresis in 
conjunction with high-dose corticosteroids and immunosuppressive therapy was 
employed to treat symptomatic exacerbations of the disease; there is a paucity of 
evidence showing long-term benefit from such an approach (Ballare and others 
1995).  Plasmapheresis remains the cornerstone of therapy in the setting of MC-
associated renal failure, limb ischemia attributable to cryoglobulinemic vasculitis, 
and progressive motor neuropathy.  Observational data suggests that 
plasmapheresis can halt the progression of acute renal failure in 55% to 87% of 
patients, although there is no clear mortality benefit (Madore and others 1996).  
Corticosteroids are also generally advocated in patients with progressive renal 
failure or vasculitis, although there are data suggesting that they may increase 
HCV RNA viremia (Dammacco and others 1994). 
Antiviral therapy directed towards chronic HCV infection has been shown 
to be highly effective in HCV-associated MC.  Interferon-α or pegylated 
interferon-α in combination with ribavirin have been used successfully in this 
manner (Table 3.3) (Zuckerman and others 2000; Mazzaro and others 2003; 
 89
Cacoub and others 2005; D'Amico and others 2005; Mazzaro and others 2005).  
Cacoub et al. reported complete clinical responses in eight of nine patients with 
HCV-MC at 18 month follow-up after treatment with pegylated interferon-α plus 
ribavirin for a mean of 13.5 months (Cacoub and others 2005).  Mazzaro et al. 
also reported favorable responses in eighteen patients with HCV-MC treated with 
pegylated interferon-α plus ribavirin, although 44% (8 patients) relapsed both 
virologically and clinically within a few weeks after cessation of therapy (Mazzaro 
and others 2005). 
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Table 3.3: Summary of trials examining interferon-α (IFN-α) or pegylated IFN-α with ribavirin in 
the setting of HCV-associated mixed cryoglobulinemia 
Year 
 
Authors 
 
No. of 
patients 
Treatment Complete 
Virologic 
Response* 
(%) 
 
Complete 
Immunologic 
Response** 
(%) 
 
Complete 
Clinical 
Response 
(%) 
 
Sustained 
Response 
(Clinical or 
Immunologic) 
(%) 
 
2005 D’Amico et 
al 
25 IFN-α 
plus 
ribavirin 
(6 – 12 
months) 
100 96 ND ND 
2005 Cacoub et 
al. 
9 Pegylated 
IFN- α 
plus 
rivavirin 
(10 – 26 
months) 
78 56 89 89-100 
2005 Mazzaro et 
al. 
18 Pegylated 
IFN-α 
plus 
rivavirin 
(48 
weeks) 
83 56-100 89 44 
2003 Mazzaro et 
al. 
27 IFN-α 
plus 
rivavirin 
(1 year) 
18 33 85 30 
2000 Zuckerman 
et al. 
9 IFN-α 
plus 
rivavirin 
(6 
months) 
22 78 100 ND 
ND- no data 
*Defined in all studies as achievement of undetectable viral load 
**Reduction in cryocrit or rheumatoid factor concentration 
Adapted from: (Zuckerman and others 2000; Mazzaro and others 2003; Cacoub and others 2005; D'Amico 
and others 2005; Mazzaro and others 2005) 
 
Rituximab, which is a chimeric monoclonal antibody directed towards 
CD20, is a novel therapy to be tried in HCV-associated MC and appears to be 
useful based on limited but numerous anecdotal studies (Zaja and others 1999; 
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Basse and others 2005; Bruchfeld and others 2006; Quartuccio and others 
2006a; Scheinfeld 2006; Seror and others 2006).  
 
Non-Hodgkin’s Lymphoma 
 
Disease. 
 
Each year, 54,000 people in the United States are diagnosed with non-
Hodgkin’s lymphoma (NHL).  NHL is a set of malignant diseases arising from 
lymphoid tissues (B or T lymphocytes).  Given the multiplicity of subsets of NHL, 
epidemiological studies regarding causative factors have not been satisfactorily 
conducted in comparison to other malignant diseases.  However, several 
possible causative factors have been identified, including pesticides, blood 
transfusion, immunodeficiency, radiation, smoking and several types of diet, as 
summarized previously (Matsuo and others 2001).   
 
Prevalence. 
 
The data linking HCV infection to NHL are significant but show 
considerable variation (0-42%) (Kashyap and others 1998; Germanidis and 
others 1999).  Epidemiologic studies support a role for HCV in the development 
of NHL as well as multiple myeloma (Ohsawa and others 1999; Duberg and 
others 2005), but others have failed to show significance (Rabkin and others 
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2002).  An interesting parallel is data showing that random bone marrow biopsies 
of HCV positive persons reveal a lymphoproliferative disorder 25-40% of the time 
(Ferri and others 1994; Rasul and others 1999).  One case control study from 
Italy found that HCV infection increased the risk for NHL 50-fold in the liver or 
salivary glands--greater than the relative risk for hepatocellular carcinoma.  The 
same study found a 4-fold increase of lymphoma in other sites (De Vita and 
others 1998). 
 
Clinical Manifestations 
 
Numerous NHL tumor types associated with HCV infection have been 
reported (Silvestri and others 1998), with follicular and lymphoplasmacytoid 
lesions being the most common.  Extranodal involvement is common (found in 
65% of individuals with HCV), with liver and salivary glands being over-
represented (De Vita and others 1997; Zuckerman and others 1997).  Individuals 
with NHL present with symptoms related to enlargement of lymph nodes that 
may be located throughout the lymphatic system.  Visceral involvement with NHL 
may remain occult for prolonged periods prior to diagnosis.  A subset of 
individuals will develop symptoms such as fever, night sweats, and weight loss 
that may bring them to medical attention. 
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Pathogenesis. 
 
While it is clear that individuals with chronic HCV infection and hepatitis 
leading to cirrhosis often develop hepatocellular carcinomas, the direct 
oncogenic potential of HCV is controversial.  Such a role cannot be completely 
ruled out, since, e.g., HCV core protein has been reported to be involved in 
transformation of cells to malignant phenotypes (Ray and others 1996).  HCV 
does show some lymphotrophic specificity but only in relatively small numbers of 
peripheral blood mononuclear cells (PBMC) (Zignego and Brechot 1999), and 
perhaps only under abnormal conditions such as immunosupression (Muratori 
and others 1996; Laskus and others 2002) or cell transformation (Sung and 
others 2003).  The preponderance of data suggests that HCV-associated 
lymphomas arise from abnormal B cell proliferation, with the mechanisms 
outlined previously in this review.   
 
Management. 
 
As the potential of HCV to clonally expand B-lymphocytes and promote 
lymphomagenesis has been further elucidated, there have been several small 
trials examining the response of HCV-associated B-cell lymphoma to antiviral 
therapy. Zuckerman et al. reported complete hematologic responses and 
regression of B-cell clonality in thirteen of fifteen patients with chronic HCV 
infection and t(14:18) translocation or IgH rearrangement, treated with either 
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interferon-α or interferon-α and ribavirin for 6 to 12 months (Zuckerman and 
others 2001).  Vallisa et al. also reported complete or partial hematologic 
responses in nine of twelve patients with HCV-associated, low grade B-cell 
lymphoma treated with pegylated interferon-α and ribavirin for 6 to 12 months, 
although molecular remission was not achieved as in the Zuckerman trial (Vallisa 
and others 2005).  Whether antiviral therapy for HCV-associated B-cell 
lymphoma should supplant or be added to conventional chemotherapy, including 
rituximab, is unclear as there have been no supporting clinical studies. 
 
Membranoproliferative Glomerulonephritis (MPGN) 
 
Disease. 
 
MPGN is a disease that affects the glomeruli of the kidney.  It is 
characterized by endocapillary proliferation, monocytic infiltration, double contour 
membranes, large eosinophilic, PAS-positive intraluminal deposits and vasculitis 
of the small and medium sized renal arteries (Fornasieri and D'Amico 1996).  
Electron microscopy indicates subendothelial deposits that may have structure 
similarities to cryoglobulins (Cordonnier and others 1975).  MPGN appears to 
occur predominantly with type II cryoglobulins (Pucillo and Agnello 1994; 
Fornasieri and D'Amico 1996).  mRF appears to be a critical element in 
deposition of cryoglobulins in the glomeruli (Fornasieri and D'Amico 1996) and 
since HCV infection produces relatively high concentrations of mRF (Pucillo and 
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Agnello 1994), this may be a reason for the predominance of HCV in 
cryoglobulinemic glomerulonephritis. 
 
Prevalence. 
 
Reports linking HCV-related mixed cryoglobulinemia to MPGN find this 
association in 33% (Agnello 2000) to 81% (Misiani and others 1992) of cases.  
Data linking HCV infection as a whole to MPGN are more controversial.  Reports 
have been published supporting and opposing this premise.  Neither argument is 
convincing since studies to detect and characterize RF in MPGN lesions in the 
absence of cryoglobulinemia and B cell clonal analysis that can detect mRF B 
cells in the absence of cryoglobulinemia have not been performed. 
 
Clinical Manifestations 
 
The average patient with renal disease associated with HCV infection is 
recognized when diagnosed with nephritic syndrome (71%).  Most will have 
serum albumin <3 g/dl with mild renal insufficiency (72%).  Over time, a relatively 
small number may progress to dialysis (Fornasieri and D'Amico 1996). Most of 
these patients will have detectable cryoglobulins (59% initially – 85% overall) but 
only 44% will present with extra-renal manifestations of cryoglobulinemia.  
Clinical presentation of liver involvement is not a given.  Up to 82% will show no 
clinical manifestations of liver disease.  However, up to 88% will have an 
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abnormal liver biopsy consistent with chronic HCV infection (Fornasieri and 
D'Amico 1996).  As in primary MC disease, complement levels will also be 
depressed in most of these patients (Misiani and others 1992). 
 
Pathogenesis 
 
Renal biopsy will generally reveal endocapillary proliferation, monocytic 
infiltration, and double contour membranes; all morphological features consistent 
with immune complex disease.  Detection of HCV RNA in the affected glomeruli 
is inconsistent due to the high levels of RF-induced artifact.  Notable is the fact 
that RF from patients with type II MC shows a high affinity for cellular fibronectin, 
which is highly concentrated in the glomerular mesangium.  This has led to 
speculation that RF induces deposition of Ig in the glomerulus irrespective of 
HCV infection (Fornasieri and D'Amico 1996). 
 
Management. 
 
Antiviral therapy aimed at chronic HCV infection remains the most 
effective treatment for HCV-associated MPGN, although recent studies using 
rituximab are quite encouraging. Interferon-α and pegylated interferon-α both in 
combination with ribavirin have been used successfully in this regard and have 
been shown to halt the progression of renal failure in such patients (Giannico and 
others 2000; Loustaud-Ratti and others 2002; Sabry and others 2002).  While 
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there is concern over the use of ribavirin in patients with renal insufficiency 
whose threshold for hemolytic anemia is lowered, its combination with interferon 
is advocated in these patients as long as its dose is titrated to account for a lower 
creatinine clearance (Orlent and others 2005). As noted, very recent studies 
suggest a role for rituximab in treating HCV-related glomerulonephritis 
(Roccatello and others 2004; Garini and others 2005; Quartuccio and others 
2006b). 
 
Other Diseases 
 
 Evidence has been published linking a number of diseases to HCV 
infection.  In general, more research needs to be done to prove or disprove these 
links.  For example, HCV has been repeatedly linked to progressive declines in 
pulmonary function in patients with underlying lung diseases such as asthma and 
chronic obstructive pulmonary disease (COPD) (Kanazawa and others 2003; 
Kanazawa and Yoshikawa 2004; Moorman and others 2005a). In patients who 
already had a diagnosis of COPD, chronic HCV infection led to a more rapid 
decline in forced expiratory volume (FEV1) and diffusing capacity for carbon 
monoxide (DLCO), findings that were abrogated in those treated with interferon 
(Kanazawa and others 2003).  In a recent 6-year prospective trial, asthmatic 
patients with chronic HCV who did not respond to interferon had greater impaired 
reversibility to bronchodilators when compared to either HCV-negative controls or 
to HCV-positive individuals who responded to interferon (Kanazawa and 
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Yoshikawa 2004).  Some data suggests that HCV infection may alter 
acetylcholine-mediated airway tone (Kanazawa and Yoshikawa 2004).  We have 
shown that HCV core protein can alter IL-8 cytokine expression in pulmonary 
fibroblasts, mediated by p38 MAPK (Moorman and others 2005b).  Other smaller 
studies also suggest a role for HCV infection in various pulmonary diseases, 
including idiopathic pulmonary fibrosis (Manganelli and others 1996; Idilman and 
others 2002). 
 
Expert Commentary 
 
While HCV infection has in the past been primarily considered a disease 
of the liver, it is now clear that this systemic infection leads to serious health 
issues beyond just the propensity to lead to chronic hepatitis and cirrhosis.  The 
majority of the diseases outlined in this review are at their core disorders of 
immune signaling.  HCV gene products such as envelope and core proteins and 
NS5A appear to have significant effects on host immune responses, and these 
may ultimately also facilitate the establishment of viral chronicity following acute 
infection.  The lack of latency with this particular virus supports the existence of 
viral mechanisms by which host immune responses are either usurped or 
avoided in an effort to establish chronicity. 
  For the majority of individuals who do go on to chronic HCV infection, the 
consequences on the immune system appear to persist.  While there are multiple 
lines of evidence suggesting that HCV can be an immunosuppressive virus, the 
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authors firmly believe that it is more accurate to state that HCV is 
immundysregulatory.   We and others have consistently found differential effects 
on B and T lymphocyte function in the setting of both clinical disease and in in 
vitro studies, with B cells exhibiting profiles consistent with activation and CD4+ 
and CD8+ T cells exhibiting altered or impaired cytokine and receptor 
expressions, proliferation, and cell survival.  The immune-associated disease 
states that are observed in the setting of chronic HCV likely represent the results 
of a complex interplay between these dysregulated immune responses (Figure 
3.3).   
 
  
 
Figure 3.3  Immunodysregulatory aspects of chronic HCV infection based on published studies.  
CTL: Cytoxic T lymphocyte; IFN: interferon; IL: Interleukin; MAPK: Mitogen-activated protein kinase; 
MHC: Major histocompatability complex; MPGN: Membraneoproliferative glomerulonephritis
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In contrast to HIV infection, characterized by a very dramatic loss of CD4+ 
T cells and extreme immunosuppression, chronic HCV infection leads to 
dysregulated immune responses that are generally more subtle and certainly 
more variable within a given infected individual.   Not every infected patient will 
develop mixed cryoglobulinemia, for example, but it would not be surprising to us 
if the majority of HCV-infected patients exhibit altered B cell responses to some 
degree when assayed in detail.  We believe that translational studies focusing on 
individuals with HCV-associated immune conditions will be the most fruitful 
approach to determining how HCV and its gene products are altering the specific 
arms of host immunity.    
 Unfortunately, much of the data regarding HCV-associated immune 
dysfunction is derived from small populations and the data are often anecdotal.  
The difficulty in accruing large numbers of affected individuals could be offset by 
a multicenter approach to studying these diseases.  Such an approach would be 
excellent for facilitating clinical trials and translational studies and would better 
define the specific immune-related issues that occur in the setting of HCV 
infection. 
 In terms of therapy, there are a fair amount of clinical data suggesting that 
combination therapy with interferon-α and ribavirin will ameliorate many of the 
HCV-associated conditions to some extent, particularly in interferon responders.  
In addition, it is of course desirable to completely eradicate this potentially 
curable disease if at all possible to avoid not only immunodysregulatory diseases 
but chronic hepatitis and all of its sequelae.  All individuals with HCV infection 
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should ideally be evaluated for treatment and offered combination therapy if 
appropriate, although in practice this has not been the rule for a multitude of 
reasons ranging from cost to toxicity of treatment to social barriers to care.  
These patients need close clinical follow up, immunizations, and teaching 
regarding lifestyle alterations including alcohol cessation. Treatment by either a 
hepatologist or infectious diseases specialist is recommended because current 
treatment options are quite toxic and require intense monitoring. 
 Therapy with rituximab is perhaps the most exciting modality that has 
emerged for individuals with immunodysregulatory diseases associated with 
HCV.  Although still primarily anecdotal, the limited data do suggest that targeting 
of B cells may be relatively effective for several of the conditions outlined herein.  
The authors believe that individuals with HCV infection who are either not eligible 
for or do not respond to combination interferon-α and ribavirin therapy, or who 
have persistent immune disease despite therapy, should be considered for 
treatment with rituximab and ideally should be enrolled in ongoing clinical trials 
with this drug.  
 
Five-year View 
 
It is likely that within 5 years there will be much more clinical data 
confirming the efficacy of drugs such as rituximab in treating HCV-associated 
diseases.  Anecdotal studies throughout the literature are quite encouraging for 
this treatment, which targets B cells in particular and has comparatively few side 
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effects.  Clinical trials with rituximab are enrolling for the treatment of 
cryoglobulinemic vasculitis, NHL, and Sjogren’s syndrome, but other HCV-
associated conditions will assuredly be targeted and clinical data are 
forthcoming.   
Although treatment of the underlying HCV infection does lead to 
improvement in some of these diseases, our current regimens of pegylated 
interferon-α and ribavirin are fraught with side effects and cure less than half of 
our infected patients, depending on their HCV genotype.  A large number of new 
treatments, however, are now in early phase clinical trials and promise improved 
sustained virologic responses.  These include novel protease, RNA polymerase, 
and RNA helicase inhibitors.  The ability to clear infection in the majority of 
individuals may be a reality for clinicians in the very near future.  
 
Key Issues 
 
• Hepatitis C virus (HCV) can dysregulate host immune responses through 
interactions with host proteins and perturbation of signal transduction 
cascades; this immunodysregulation may afford the virus the opportunity 
to persist and to facilitate the development of immune disorders.  
• Mixed cryoglobulinemia is strongly associated with HCV, and renal 
disease and lymphoma manifest at least some overlap with 
cryoglobulinemia.   
• The interaction of the HCV gene products with key aspects of the host 
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immune system seems to be important in the pathophysiology of several 
of the extrahepatic manifestations of HCV.   
• Antiviral therapy and/or treatment targeted at B cell populations are 
efficacious for certain immune-related manifestations of HCV infection.  
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CHAPTER 4 
 
DISCUSSION 
 
Despite the advances made in the area of HCV research we are still left 
with many unanswered questions and few good options.  There is no vaccine 
available for HCV; there is no treatment that is consistently effective from patient 
to patient and viral genotype to genotype; and finally, there is no conclusive 
evidence that explains how HCV evades the human immune system and 
establishes a chronic infection.  In these studies we attempt to identify one 
possible pathway that the virus may exploit to establish a chronic infection.   
It has been established that extracellular hepatitis C core protein will bind 
to the complement receptor gC1qR (Kittlesen and others 2000) and subsequently 
suppress T-cell activity in vitro.  This suppressive ability mimics C1q, which is the 
natural ligand for gC1qR (Chen and others 1994), and can be blocked by the 
addition of anti-gC1qR.  Given that a strong T-cell response is necessary to 
eliminate viral infections any perturbations of the T-cell response suggests a 
possible mechanism for establishing a chronic viral infection. 
Very recent data have shown that the expression of PD-1/PDL-1 to be 
related to whether an acute viral challenge will be cleared by the host or develop 
into a chronic infection.  These data show that PD-1/PDL-1 is upregulated in a 
chronic infection versus an acute infection and may play a role in T-cell anergy.  
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Of most importance, these studies have shown that anergic T-cells can be 
rescued by blocking the ligation of PDL-1 to PD-1. 
We began these studies by determining the PD-1 expression levels on 
PBMCs isolated from healthy donors versus PBMCs isolated from persons 
chronically infected with HCV.  Upon activation of these PBMCs by anti-
CD3/CD28 or no activation, we were able to demonstrate that in fact PD-1 
expression is upregulated on PBMCs from the chronically infected donors when 
compared to the healthy donors.  We were further able to show that PD-1 is also 
upregulated on the CD4+ and CD8+ subpopulations.  We were also able to 
demonstrate that the ligand for PD-1, PDL-1, is also upregulated on chronically 
infected persons.  Moreover, when isolated PBMCs were treated with other viral 
proteins, such as HCV NS3, HIV Tat, and gp120, no change in PD-1 expression 
was noted.  Finally, to rule out the possibility that we had started with different 
lymphocyte phenotype subpopulations, we compared the PD-1/PDL-1 
expression levels of CD45RA and CD45RO on T-cells isolated from chronically 
infected persons.  In both a stimulated and unstimulated setting we show no 
difference in the levels of PD-1/PDL-1 expression. 
Our data suggest that PD-1/PDL-1 are upregulated in response to the 
setting of a chronic HCV infection; how this occurs is unknown but seems likely 
related to a hepatitis C viral product.  Because previous data have shown that the 
HCV core protein has suppressive effects on T-cells, we investigated whether 
HCV core protein would have an effect on the expressed levels of PD-1 and 
PDL-1.  We demonstrated that HCV core will increase the expression of PD-1 in 
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a dose dependent manner and that C1q will also increase the expression of PD-1 
when compared to a control protein.  This upregulation of expression, as induced 
by HCV core, was also shown to be present on CD4+ and CD8+ T-cells.   
Next, to determine if a the upregulation of PD-1 is mediated through HCV 
core binding to gC1qR and to further support the link between core and PD-1 
expression, we measured the levels of PD-1 mRNA in T-cells exposed to HCV 
core.  We found consistent upregulation of the message, beginning as early as 6 
hours, after treatment with the core protein.  We also employed anti-gC1qR in 
these experiments and found that the antibody inhibited core’s ability to increase 
the level of PD-1 message.  To support the gC1qR findings we again measured 
the expression level of PD-1, this time in healthy donor cells treated with core 
alone, core plus a non-specific antibody, or core plus anti-gC1qR.  Again, we 
found that anti-gC1qR inhibited core’s ability to effect PD-1 changes, e.g. PD-1 
upregulation. 
Our last set of experiments were designed to determine if blocking the PD-
1/PDL-1 interaction in the presence of core protein would restore T-cell function.  
We found that CD4+ and CD8+ cells in the presence of core protein show a 
suppression of CD69 (a T-cell activation marker); yet, these same cells 
demonstrated an increase of CD69 when treated with anti-PD-1 or anti-PDL-1.  
We were also able to show that blocking with anti-PD1 or anti-PDL-1 will partially 
restore T-cell proliferation (in the presence of core protein) and will decrease the 
amount of apoptosis of T-cells (in the presence of core protein). 
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HCV core is a known immunomodulatory viral antigen that circulates in the 
plasma of infected individuals.  Whether core is the cause or a cause of chronic 
infection remains to be determined.  Regardless of the role core is eventually 
discovered to have, it seems clear that levels of PD-1 and PDL-1 do have a role 
in establishing a chronic infection.   
Data supporting the importance of PD-1 and its role in the immune 
response are many; evidence suggests that PD-1/PDL-1 involvement is normal 
for proper immune tolerance, autoimmune responses, and antitumor or antiviral 
immune evasion (Nishimura and Honjo 2001; Dong and others 2002; Iwai and 
others 2003; Chen 2004; Khoury and Sayegh 2004); the recent discovery that 
PD-1 is upregulated on exhausted T-cells during a chronic viral infection in mice 
(Barber and others 2006) and their subsequent reactivation by blocking the 
interaction between PD-1 and PDL-1.  Interestingly, this exhaustion of host T-
cells as a means of immune evasion may also be a mechanism employed by 
other persistent viruses in humans, such as HIV (Day and others 2006; Freeman 
and others 2006; Petrovas and others 2006; Trautmann and others 2006a).  The 
data so far make a strong suggestion for the importance of PD-1 in general and 
its potential role in the establishment of viral chronicity.  If this is indeed the case 
then either blocking the PD-1/PDL-1 interaction or blocking the HCV core 
protein/gC1qR interaction would offer potential new treatment options for 
management of hepatitis C. 
Our lab has also recently shown that suppressor of cytokine signaling-1 
(SOCS-1) is also upregulated in T-cells in the presence of HCV core.  SOCS-1, 
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like PD-1, is a negative regulator of T-cells.  With this knowledge that two known 
negative regulators of T-cells are upregulated by HCV core protein the next step 
will be to examine the role of PD-1 and SOCS-1 in regulating T-cell signaling 
during HCV infection as described in Figure 4.1. 
 
 
Figure 4.1  Schematic representation of experiments designed to delineate signaling by negative 
modulators PD-1 (A) or SOCS-1 (B) during HCV core/gC1qR-mediated T cell inhibition. 
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 CHAPTER 5 
 
ADDITIONAL INFORMATION 
 
 In addition to the data presented and discussed in chapters one through 
three, we also attempted to further characterize the hepatitis C core protein.  Our 
hypothesis was that HCV core protein inhibited specific T-cell signaling pathways 
mediated by its ability to bind to gC1qR and this inhibition subsequently inhibited 
the T-cell response.  Our overall strategy was to create and express mutations of 
the HCV core protein and compare the mutated core effects on T-cell responses 
to the wild type core effects on T-cell responses. 
 We employed a scanning alanine mutagenesis technique to generate the 
core mutants.  We were able to create 10 mutations (as confirmed by 
sequencing) in the area of HCV core deemed most likely to contain the binding 
site to gC1qR.  We were then able to clone these mutants into an E. coli 
expression system that would express the now mutant proteins with a 6 histidine 
tag.  We then attempted expression and were able to express the mutant 
proteins and confirm the expression via western blot and coomassie gel.  We 
were also able to purify the proteins by using Ni+ columns.  We were less 
successful in our attempts to concentrate the protein.  Concentration attempts 
seemed to cause the core protein to ‘disappear’ as we could see no signal on 
post-concentration analysis.  Efforts to block the concentration system using 
unrelated proteins had no positive effect. 
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 We then compared T-cell responses using proteins that we were able to 
express and found no differences.  Whether this was due to small concentrations 
of the mutant proteins or other reasons is unknown.  We ultimately abandoned 
this avenue of research but feel that with adequate funding and time that needed 
progress could be accomplished in this area. 
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